CA2519711C - Implantable medical device with beneficial agent concentration gradient - Google Patents
Implantable medical device with beneficial agent concentration gradient Download PDFInfo
- Publication number
- CA2519711C CA2519711C CA2519711A CA2519711A CA2519711C CA 2519711 C CA2519711 C CA 2519711C CA 2519711 A CA2519711 A CA 2519711A CA 2519711 A CA2519711 A CA 2519711A CA 2519711 C CA2519711 C CA 2519711C
- Authority
- CA
- Canada
- Prior art keywords
- matrix
- agent
- therapeutic agent
- implantable medical
- medical device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/041—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
- A61L2300/604—Biodegradation
Abstract
The implantable medical devices are configured to release at least one therapeutic agent from a matrix affixed to the implantable body with a release profile which is programable to the agent and treatment. The matrix is formed such that the concentration of the therapeutic agent in the matrix varies as a gradient relative to a surface of the implantable body. The change in the concentration gradient of the agent in the matrix directly controls the rate of elution of the agent from the matrix. The therapeutic agent matrix can be disposed in the stent or on surfaces of the stent in various configurations, including within volumes defined by the stent, such as openings, holes, or concave surfaces, as a reservoir of agent, and alternatively as a coating on all or a portion of the surfaces of the stent structure.
Description
IMPLANTABLE MEDICAL DEVICE WITH BENEFICIAL
AGENT CONCENTRATION GRADIENT
FIELD OF THE INVENTION
[00021 The invention relates to a therapeutic agent delivery device which has a concentration gradient of the therapeutic agent contained within a matrix to provide release kinetics which are specifically programable for the particular agent, administration period, and release rate desired.
BACKGROUND
10003] Implantable medical devices are sometimes used for delivery of a therapeutic agent, such as a drug, to an organ or tissue in the body. It is hoped that these devices may deliver agents to a wide variety of bodily systems to provide a wide variety of treatments.
[00041 One implantable medical device which has been used for local delivery of therapeutic agents is the coronary stent. Coronary stents are typically introduced percutaneously, and transported transluminally until positioned at a desired location.
These devices are then expanded either mechanically, such as by the expansion of a mandrel or balloon positioned inside the device, or expand themselves by releasing stored energy upon actuation within the body. Once expanded within the lumen, these devices, called stents, become encapsulated within the body tissue and remain a permanent implant.
[0005] Of the many problems that may be addressed through stent-based local delivery of therapeutic agents, one of the most important is restenosis.
Restenosis is a major complication that can arise following vascular interventions such as angioplasty and the implantation of stents. Simply defined, restenosis is a wound healing process that reduces the vessel lumen diameter by extracellular matrix deposition, neointimal hyperplasia, and vascular smooth muscle cell proliferation, and which may ultimately result in renarrowing or even reocclusion of the lumen.
Despite the introduction of improved surgical techniques, devices, and pharmaceutical agents, the overall restenosis rate is still reported in the range of 25%
to 50% within six to twelve months after an angioplasty procedure. To treat this condition, additional revascularization procedures are frequently required, thereby increasing trauma and risk to the patient.
[0006] One of the techniques under development to address the problem of restenosis is the use of surface coatings of various therapeutic agents on stents. U.S.
Pat. No. 5,716,981, for example, discloses a stent that is surface-coated with a composition comprising a polymer carrier and paclitaxel (a well-known compound that is commonly used in the treatment of cancerous tumors). Known surface coatings, however, can provide little actual control over the release kinetics of therapeutic agents. These coatings are generally very thin, typically 5 to 8 microns deep. The surface area of the stent, by comparison is very large, so that the entire volume of the therapeutic agent has a very short diffusion path to discharge into the surrounding tissue. The ability to shape the release profiles from such systems is severely limited.
[0007] Accordingly, it would be desirable to provide a therapeutic agent delivery device with the ability to program the release kinetics to the particular agent, administration period, and release rate desired.
AGENT CONCENTRATION GRADIENT
FIELD OF THE INVENTION
[00021 The invention relates to a therapeutic agent delivery device which has a concentration gradient of the therapeutic agent contained within a matrix to provide release kinetics which are specifically programable for the particular agent, administration period, and release rate desired.
BACKGROUND
10003] Implantable medical devices are sometimes used for delivery of a therapeutic agent, such as a drug, to an organ or tissue in the body. It is hoped that these devices may deliver agents to a wide variety of bodily systems to provide a wide variety of treatments.
[00041 One implantable medical device which has been used for local delivery of therapeutic agents is the coronary stent. Coronary stents are typically introduced percutaneously, and transported transluminally until positioned at a desired location.
These devices are then expanded either mechanically, such as by the expansion of a mandrel or balloon positioned inside the device, or expand themselves by releasing stored energy upon actuation within the body. Once expanded within the lumen, these devices, called stents, become encapsulated within the body tissue and remain a permanent implant.
[0005] Of the many problems that may be addressed through stent-based local delivery of therapeutic agents, one of the most important is restenosis.
Restenosis is a major complication that can arise following vascular interventions such as angioplasty and the implantation of stents. Simply defined, restenosis is a wound healing process that reduces the vessel lumen diameter by extracellular matrix deposition, neointimal hyperplasia, and vascular smooth muscle cell proliferation, and which may ultimately result in renarrowing or even reocclusion of the lumen.
Despite the introduction of improved surgical techniques, devices, and pharmaceutical agents, the overall restenosis rate is still reported in the range of 25%
to 50% within six to twelve months after an angioplasty procedure. To treat this condition, additional revascularization procedures are frequently required, thereby increasing trauma and risk to the patient.
[0006] One of the techniques under development to address the problem of restenosis is the use of surface coatings of various therapeutic agents on stents. U.S.
Pat. No. 5,716,981, for example, discloses a stent that is surface-coated with a composition comprising a polymer carrier and paclitaxel (a well-known compound that is commonly used in the treatment of cancerous tumors). Known surface coatings, however, can provide little actual control over the release kinetics of therapeutic agents. These coatings are generally very thin, typically 5 to 8 microns deep. The surface area of the stent, by comparison is very large, so that the entire volume of the therapeutic agent has a very short diffusion path to discharge into the surrounding tissue. The ability to shape the release profiles from such systems is severely limited.
[0007] Accordingly, it would be desirable to provide a therapeutic agent delivery device with the ability to program the release kinetics to the particular agent, administration period, and release rate desired.
SUMMARY OF THE INVENTION
[0008] The present invention relates to implantable medical devices for programable delivery of a therapeutic agent, methods of forming implantable medical devices, and methods for delivering therapeutic agents from implantable medical devices.
[0009] In accordance with one aspect of the invention, an implantable medical device configured to release at least one therapeutic agent therefrom is provided, wherein the device includes an implantable body; and a matrix affixed to the 1o implantable body. The matrix contains the at least one therapeutic agent therein, and the matrix is formed such that the concentration of the therapeutic agent in the matrix varies as a continuous gradient relative to a surface of the implantable body.
[0010] In accordance with another aspect of the invention, a method of forming an implantable medical device configured to release at least one therapeutic agent therefrom is provided. The therapeutic agent is disposed in a matrix affixed to the body of the implantable medical device, and the concentration of the at least one therapeutic agent in the matrix varies as a continuous gradient relative to a surface of the body of the implantable medical device. The method involves forming a first homogeneous solution comprising the at least one therapeutic agent mixed with a polymeric binder, applying the first homogeneous solution to the body of the implantable medical device, solidifying the first homogeneous solution, thereby forming a first portion of the matrix, forming a second homogeneous solution comprising the polymeric binder, applying the second homogeneous solution to the first portion of the matrix, thereby at least partially liquifying the first portion of the matrix, and solidifying the second homogeneous solution, thereby forming a second portion of the matrix, wherein the concentration of the at least one therapeutic agent in the matrix is different in the first and second portions of the matrix.
[0008] The present invention relates to implantable medical devices for programable delivery of a therapeutic agent, methods of forming implantable medical devices, and methods for delivering therapeutic agents from implantable medical devices.
[0009] In accordance with one aspect of the invention, an implantable medical device configured to release at least one therapeutic agent therefrom is provided, wherein the device includes an implantable body; and a matrix affixed to the 1o implantable body. The matrix contains the at least one therapeutic agent therein, and the matrix is formed such that the concentration of the therapeutic agent in the matrix varies as a continuous gradient relative to a surface of the implantable body.
[0010] In accordance with another aspect of the invention, a method of forming an implantable medical device configured to release at least one therapeutic agent therefrom is provided. The therapeutic agent is disposed in a matrix affixed to the body of the implantable medical device, and the concentration of the at least one therapeutic agent in the matrix varies as a continuous gradient relative to a surface of the body of the implantable medical device. The method involves forming a first homogeneous solution comprising the at least one therapeutic agent mixed with a polymeric binder, applying the first homogeneous solution to the body of the implantable medical device, solidifying the first homogeneous solution, thereby forming a first portion of the matrix, forming a second homogeneous solution comprising the polymeric binder, applying the second homogeneous solution to the first portion of the matrix, thereby at least partially liquifying the first portion of the matrix, and solidifying the second homogeneous solution, thereby forming a second portion of the matrix, wherein the concentration of the at least one therapeutic agent in the matrix is different in the first and second portions of the matrix.
[0011] In accordance with an additional aspect of the invention, a method of forming an implantable medical device configured to release at least one therapeutic agent therefreom is provided. The therapeutic agent is disposed in a matrix affixed to a body of the implantable medical device, and a concentration of the at least one therapeutic agent in the matrix varies as a continuous gradient relative to a surface of the implantable medical device body. The method involves forming a homogeneous solution comprising a polymeric binder and a solvent, evaporating the solvent in the homogeneous solution, thereby forming a matrix, exposing the matrix to a solution comprising the therapeutic agent for a time sufficient to produce a partial diffusion of the therapeutic agent into the matrix such that the concentration of the therapeutic agent varies in the matrix, and affixing the matrix to the implantable medical device body.
[0012] In accordance with a further aspect of the invention, a method for treating a patient by local delivery of at least one therapeutic agent is provided. The method involves delivering an implantable medical device into the body of a patient, the implantable medical device having a matrix affixed to a body of the implantable medical device with concentration of the at least one therapeutic agent in the matrix varying as a continuous gradient relative to a surface of the body of the implantable medical device. The method further involves delivering the therapeutic agent at a release rate and over an administration period determined by the gradient of therapeutic agent in the matrix.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] The invention will now be described in greater detail with reference to the preferred embodiments illustrated in the accompanying drawings, in which like elements bear like reference numerals, and wherein:
[0014] FIG. 1 is a perspective view of one example of a stent according to the present invention.
[0012] In accordance with a further aspect of the invention, a method for treating a patient by local delivery of at least one therapeutic agent is provided. The method involves delivering an implantable medical device into the body of a patient, the implantable medical device having a matrix affixed to a body of the implantable medical device with concentration of the at least one therapeutic agent in the matrix varying as a continuous gradient relative to a surface of the body of the implantable medical device. The method further involves delivering the therapeutic agent at a release rate and over an administration period determined by the gradient of therapeutic agent in the matrix.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] The invention will now be described in greater detail with reference to the preferred embodiments illustrated in the accompanying drawings, in which like elements bear like reference numerals, and wherein:
[0014] FIG. 1 is a perspective view of one example of a stent according to the present invention.
[0015] FIG. 2 is a side view of a portion of the stent of FIG. 1.
[0016] FIG. 3 is a side cross sectional view of an example of an opening in a stent showing a matrix with one therapeutic agent having a concentration gradient.
[0017] FIG. 4 is a graph of the therapeutic agent concentration gradient of FIG.
3.
[0018] FIG. 5 is a graph of the release kinetics of the stent of FIG. 3.
[0019] FIG. 6 is a side cross sectional view of another example of an opening in a stent a matrix with one therapeutic agent having a concentration gradient.
[0020] FIG. 7 is a graph of the therapeutic agent concentration gradient of FIG.
[0016] FIG. 3 is a side cross sectional view of an example of an opening in a stent showing a matrix with one therapeutic agent having a concentration gradient.
[0017] FIG. 4 is a graph of the therapeutic agent concentration gradient of FIG.
3.
[0018] FIG. 5 is a graph of the release kinetics of the stent of FIG. 3.
[0019] FIG. 6 is a side cross sectional view of another example of an opening in a stent a matrix with one therapeutic agent having a concentration gradient.
[0020] FIG. 7 is a graph of the therapeutic agent concentration gradient of FIG.
6.
[0021] FIG. 8 is a graph of the release kinetics of the stent of FIG. 6.
[0022] FIG. 9 is a side cross sectional view of an example of an opening in a stent showing a matrix with two therapeutic agents having concentration gradients.
[0023] FIG. 10 is a graph of the therapeutic agent concentration gradients of FIG. 9.
[0024] FIG. 11 is a graph of the release kinetics of the stent of FIG. 9.
DETAILED DESCRIPTION
[0025] The invention relates to a medical device or stent having a matrix containing a therapeutic agent therein such that the concentration of agent in the matrix varies as a function of the position relative to the matrix surfaces.
The agent may be any therapeutic agent that provides a beneficial effect after the deployment of the medical device and release of the agent from the matrix into the tissue of a mammal.
[0026] First, the following terms, as used herein, shall have the following meanings:
The terms "drug" and "therapeutic agent" are used interchangeably to refer to any therapeutically active substance that is delivered to a living being to produce a desired, usually beneficial, effect.
[0027] The term "matrix" or "biocompatible matrix" are used interchangeably to refer to a medium or material that, upon implantation in a subject, does not elicit a detrimental response sufficient to result in the rejection of the matrix. The matrix typically does not provide any therapeutic responses itself, though the matrix may contain or surround a therapeutic agent, and/or modulate the release of the therapeutic agent into the body. A matrix is also a medium that may simply provide support, structural integrity or structural barriers. The matrix may be polymeric, non-polymeric, hydrophobic, hydrophilic, lipophilic, amphiphilic, and the like. The matrix may be bioresorbable or non-bioresorbable.
[0023] The term "bioresorbable" refers to a matrix, as defined herein, that can be broken down by either chemical or physical process, upon interaction with a physiological environment. The matrix can erode or dissolve. A bioresorbable matrix serves a temporary function in the body, such as drug delivery, and is then degraded or broken into components that are metabolizable or excretable, over a period of time from minutes to years, preferably less than one year, while maintaining any requisite structural integrity in that same time period.
[0029] The term "openings" includes both through openings and recesses.
[0030] The term "pharmaceutically acceptable" refers to the characteristic of being non-toxic to a host or patient and suitable for maintaining the stability of a therapeutic agent and allowing the delivery of the therapeutic agent to target cells or tissue.
[0031] The term "polymer" refers to molecules formed from the chemical union of two or more repeating units, called monomers. Accordingly, included within the term "polymer" may be, for example, dimers, trimers and oligomers. The polymer may be synthetic, naturally-occurring or semisynthetic. In preferred form, the term "polymer" refers to molecules which typically have a Mw greater than about and preferably greater than about 10,000 and a Mw that is less than about 10 million, preferably less than about a million and more preferably less than about 200,000.
Examples of polymers include but are not limited to, poly-a-hydroxy acid esters such as, polylactic acid (PLLA or DLPLA), polyglycolic acid, polylactic-co-glycolic acid (PLGA), polylactic acid-co-caprolactone; poly (block-ethylene oxide-block-lactide-co-glycolide) polymers (PEO-block-PLGA and PEO-block-PLGA-block-PEO); polyethylene glycol and polyethylene oxide, poly (block-ethylene oxide-block-propylene oxide-block-ethylene oxide); polyvinyl pyrrolidone;
polyorthoesters; polysaccharides and polysaccharide derivatives such as polyhyaluronic acid, poly (glucose), polyalginic acid, chitin, chitosan, chitosan derivatives, cellulose, methyl cellulose, hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose, cyclodextrins and substituted cyclodextrins, such as beta-cyclodextrin sulfobutyl ethers; polypeptides and proteins, such as polylysine, polyglutamic acid, albumin; polyanhydrides; polyhydroxy alkonoates such as polyhydroxy valerate, polyhydroxy butyrate, and the like.
[0032] The term "primarily" with respect to directional delivery, refers to an amount greater than about 50% of the total amount of therapeutic agent provided to a blood vessel.
[0033] The term "restenosis" refers to the renarrowing of an artery following an angioplasty procedure which may include stenosis following stent implantation.
[0034] The term "liquified" is used herein to define a component which is put in a liquid state either by heating the component to a temperature higher than its melting point, or glass transition temperature, or by dissolving the component in a solvent. The typical liquified materials of the present invention will have a viscosity of less than about 10,000 centipoise, and preferably less about 1,000 centipoise, and more preferably less than about 100 centipoise.
[0021] FIG. 8 is a graph of the release kinetics of the stent of FIG. 6.
[0022] FIG. 9 is a side cross sectional view of an example of an opening in a stent showing a matrix with two therapeutic agents having concentration gradients.
[0023] FIG. 10 is a graph of the therapeutic agent concentration gradients of FIG. 9.
[0024] FIG. 11 is a graph of the release kinetics of the stent of FIG. 9.
DETAILED DESCRIPTION
[0025] The invention relates to a medical device or stent having a matrix containing a therapeutic agent therein such that the concentration of agent in the matrix varies as a function of the position relative to the matrix surfaces.
The agent may be any therapeutic agent that provides a beneficial effect after the deployment of the medical device and release of the agent from the matrix into the tissue of a mammal.
[0026] First, the following terms, as used herein, shall have the following meanings:
The terms "drug" and "therapeutic agent" are used interchangeably to refer to any therapeutically active substance that is delivered to a living being to produce a desired, usually beneficial, effect.
[0027] The term "matrix" or "biocompatible matrix" are used interchangeably to refer to a medium or material that, upon implantation in a subject, does not elicit a detrimental response sufficient to result in the rejection of the matrix. The matrix typically does not provide any therapeutic responses itself, though the matrix may contain or surround a therapeutic agent, and/or modulate the release of the therapeutic agent into the body. A matrix is also a medium that may simply provide support, structural integrity or structural barriers. The matrix may be polymeric, non-polymeric, hydrophobic, hydrophilic, lipophilic, amphiphilic, and the like. The matrix may be bioresorbable or non-bioresorbable.
[0023] The term "bioresorbable" refers to a matrix, as defined herein, that can be broken down by either chemical or physical process, upon interaction with a physiological environment. The matrix can erode or dissolve. A bioresorbable matrix serves a temporary function in the body, such as drug delivery, and is then degraded or broken into components that are metabolizable or excretable, over a period of time from minutes to years, preferably less than one year, while maintaining any requisite structural integrity in that same time period.
[0029] The term "openings" includes both through openings and recesses.
[0030] The term "pharmaceutically acceptable" refers to the characteristic of being non-toxic to a host or patient and suitable for maintaining the stability of a therapeutic agent and allowing the delivery of the therapeutic agent to target cells or tissue.
[0031] The term "polymer" refers to molecules formed from the chemical union of two or more repeating units, called monomers. Accordingly, included within the term "polymer" may be, for example, dimers, trimers and oligomers. The polymer may be synthetic, naturally-occurring or semisynthetic. In preferred form, the term "polymer" refers to molecules which typically have a Mw greater than about and preferably greater than about 10,000 and a Mw that is less than about 10 million, preferably less than about a million and more preferably less than about 200,000.
Examples of polymers include but are not limited to, poly-a-hydroxy acid esters such as, polylactic acid (PLLA or DLPLA), polyglycolic acid, polylactic-co-glycolic acid (PLGA), polylactic acid-co-caprolactone; poly (block-ethylene oxide-block-lactide-co-glycolide) polymers (PEO-block-PLGA and PEO-block-PLGA-block-PEO); polyethylene glycol and polyethylene oxide, poly (block-ethylene oxide-block-propylene oxide-block-ethylene oxide); polyvinyl pyrrolidone;
polyorthoesters; polysaccharides and polysaccharide derivatives such as polyhyaluronic acid, poly (glucose), polyalginic acid, chitin, chitosan, chitosan derivatives, cellulose, methyl cellulose, hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose, cyclodextrins and substituted cyclodextrins, such as beta-cyclodextrin sulfobutyl ethers; polypeptides and proteins, such as polylysine, polyglutamic acid, albumin; polyanhydrides; polyhydroxy alkonoates such as polyhydroxy valerate, polyhydroxy butyrate, and the like.
[0032] The term "primarily" with respect to directional delivery, refers to an amount greater than about 50% of the total amount of therapeutic agent provided to a blood vessel.
[0033] The term "restenosis" refers to the renarrowing of an artery following an angioplasty procedure which may include stenosis following stent implantation.
[0034] The term "liquified" is used herein to define a component which is put in a liquid state either by heating the component to a temperature higher than its melting point, or glass transition temperature, or by dissolving the component in a solvent. The typical liquified materials of the present invention will have a viscosity of less than about 10,000 centipoise, and preferably less about 1,000 centipoise, and more preferably less than about 100 centipoise.
[0035] The term "homogeneously disposed" refers to a mixture in which each of the components are uniformly dispersed within the matrix.
[0036] The term "heterogeneously disposed" refers to a mixture in which the components are not mixed uniformly into a matrix.
[0037] FIG. I illustrates one example of an implantable medical device in the form of a stent 10. Although the present invention will be described with reference to a stent, the invention can also be useful as other types of drug delivery implants including subcutaneous implants, embolization devices, and implants for delivery of chemotherapeutic agents.
i0 [0038] FIG. 2 is an enlarged flattened view of a portion of the stent of FIG. 1 illustrating one example of a stent structure including struts 12 interconnected by ductile hinges 20. The struts 12 include openings 14 which can be non-deforming openings containing the therapeutic agent and matrix. One example of a stent structure having non-deforming openings is shown in U.S. Patent No. 6,562,065.
[0039] The implantable medical devices of the present invention are configured to release at least one therapeutic agent from a matrix affixed to the implantable body. The matrix is formed such that the concentration of the therapeutic agent in the matrix varies as a gradient relative to a surface of the matrix affixed to the implantable body. The deposition of a coating on a surface, such as by dipping or spraying may result in the phenomenon know as blooming by which the drug migrates to the surface resulting in increased concentration at the matrix surface.
However, know coating methods do not achieve configurations in which a concentration in an area adjacent the matrix surface is less than a concentration of the drug at another part of the matrix. The present invention provides methods and devices by which an implantable medical device can be designed to achieve a particular release profile by providing a concentration gradient of drug in a homogeneous polymer matrix in which the concentration gradient is provided other than by the phenomenon of blooming.
[0036] The term "heterogeneously disposed" refers to a mixture in which the components are not mixed uniformly into a matrix.
[0037] FIG. I illustrates one example of an implantable medical device in the form of a stent 10. Although the present invention will be described with reference to a stent, the invention can also be useful as other types of drug delivery implants including subcutaneous implants, embolization devices, and implants for delivery of chemotherapeutic agents.
i0 [0038] FIG. 2 is an enlarged flattened view of a portion of the stent of FIG. 1 illustrating one example of a stent structure including struts 12 interconnected by ductile hinges 20. The struts 12 include openings 14 which can be non-deforming openings containing the therapeutic agent and matrix. One example of a stent structure having non-deforming openings is shown in U.S. Patent No. 6,562,065.
[0039] The implantable medical devices of the present invention are configured to release at least one therapeutic agent from a matrix affixed to the implantable body. The matrix is formed such that the concentration of the therapeutic agent in the matrix varies as a gradient relative to a surface of the matrix affixed to the implantable body. The deposition of a coating on a surface, such as by dipping or spraying may result in the phenomenon know as blooming by which the drug migrates to the surface resulting in increased concentration at the matrix surface.
However, know coating methods do not achieve configurations in which a concentration in an area adjacent the matrix surface is less than a concentration of the drug at another part of the matrix. The present invention provides methods and devices by which an implantable medical device can be designed to achieve a particular release profile by providing a concentration gradient of drug in a homogeneous polymer matrix in which the concentration gradient is provided other than by the phenomenon of blooming.
[0040] In one embodiment, the matrix is a polymeric material which acts as a binder or carrier to hold the agent in or on the stent and/or modulate the release of the agent from the stent. The polymeric material can be a bioresorbable or a non-bioresorbable material.
[0041] The therapeutic agent containing matrix can be disposed in the stent or on surfaces of the stent in various configurations, including within volumes defined by the stent, such as openings, holes, or concave surfaces, as a reservoir of agent, and alternatively as a coating on all or a portion of surfaces of the stent structure.
When the therapeutic agent matrix is disposed within openings in the strut structure of the stent to form a reservoir, the openings may be partially or completely filled with matrix containing the therapeutic agent.
[0042] The concentration of agent in a local region of the matrix is the sum of the amount of agent dissolved in the matrix, in a so-called solid solution morphology, and the amount dispersed in that local region of the matrix, a so-called solid emulsion morphology. The relative amount of dissolved and dispersed agent in a region is controlled by the solubility of the agent in the matrix material. When the limit of solubility of the agent in the matrix material is reached, any additional agent will be in a dispersed second phase particulate morphology.
[0043] FIG. 3 is a cross section of the stent 10 and blood vessel 100 illustrating one example of an opening 14 arranged adjacent the vessel wall with a mural surface 26 abutting the vessel wall and a luminal surface 24 opposite the mural surface. The opening 14 of FIG. 3 contains a matrix 40 with a therapeutic agent illustrated by Os in the matrix. As can be seen in the example of FIG. 3, the concentration of the therapeutic agent (Os) is highest at the luminal side of the matrix 40 and lowest at the mural side of the matrix. The luminal side 24 of the stent 10 is also provided with a barrier layer 30. The barrier layer 30 causes the therapeutic agent to be delivered primarily to the mural side 26 of the stent.
[0044] FIG. 4 illustrates graphically a concentration gradient similar to that depicted in FIG. 3 where the agent concentration in the matrix is highest in the middle of the stent or adjacent the luminally located barrier layer 30 and the agent concentration decreases moving toward the mural side of the matrix. The concentration gradient is described by the local concentration of the agent in matrix regions along a theoretical line substantially perpendicular to the surfaces of the matrix. A continuous agent concentration gradient is where the agent concentration in a volume of matrix varies in a blended fashion in moving between successive positions along the line substantially perpendicular to the matrix surface.
Thus, if the matrix surface was substantially collinear with the stent surface and the matrix was sliced into a plurality of slices substantially parallel to the stent surface, the adjacent slices will have different agent concentrations. Alternately, the matrix surface maybe contoured and the adjacent slices maybe similarly configured.
[0045] As illustrated in FIG. 3, the barrier layer 30 includes no therapeutic agent and the concentration gradient of therapeutic agent is provided in the matrix in the portion of the opening 14 not containing the barrier material. Alternatively, the barrier layer 30 may include some therapeutic agent and the concentration gradient may continue in part or all of the barrier layer.
[0046] As shown in FIG. 4, the change in agent concentration in the matrix is a continuous function of the position relative to the matrix surfaces. As shown in FIG.
5, the release kinetics of the system of FIGS. 3 and 4 can be essentially linear (essentially constant release rate over time) after an initial release. Such substantially linear release profiles are described in further detail in U.S.
Patent Publication No. 2004 /0204756 filed on February 11, 2004.
[0047] FIG. 6 illustrates a configuration of a matrix 50 in an opening 14 where the matrix and therapeutic agent concentration gradient are designed for rapid initial release of agent to the luminal side followed by a low level release for an extended time. The agent concentration in FIG. 6 is high at the luminal surface 24 of the matrix 50 and the concentration gradient will decrease steeply in the interior of the matrix. FIG. 7 illustrates the concentration gradient of the FIG. 6 example graphically. FIG. 8 illustrates the agent release over time for the example of FIGS. 6 and 7. Using careful specification of the agent concentration gradient in this example, substantially first order agent release kinetics with directionally controlled delivery may be obtained.
[0048] Since the matrix is created in a stepwise manner, as will be described below, individual chemical compositions and pharmacokinetic properties can be imparted to different areas of the matrix. Numerous useful arrangements of such matrix areas can be formed, some of which will be described herein. Each of the areas of the matrix may include one or more agents in the same or different proportions from one area to the next. The matrix may be solid, porous, or filled with other drugs or excipients. The agents maybe homogeneously disposed or heterogeneously disposed in different areas of the matrix.
[0049] FIG. 9 illustrates an example of another stent 10 having a matrix 60 containing two agents with different concentration gradients. In FIG. 9, a first agent (Drug A) represented by Os is has a concentration gradient with a maximum concentration at a luminal side 24= of the stent. A second agent (Drug B) represented by s has a concentration gradient with a maximum concentration at a mural side of the matrix. This configuration results in the delivery of two drugs in different primary delivery directions. For example, an antithrombotic agent (Drug A) may be delivered primarily luminally at a relatively quick initial release rate while an antirestenotic agent (Drug B) is delivered primarily murally with a different delivery profile having a more constant release rate and longer administration period.
FIG.
10 illustrates graphically the agent concentration gradients of the first agent (Drug A) and the second agent (Drug B). FIG. 11 illustrates the cumulative release of the first and second agents (Drug A and Drug B) over time.
[0050] It is envisioned that the continuous agent concentration gradient will take a variety of forms depending on the desired administration period and rate of elution of the agent into the tissue surrounding the stent, as well as the desired direction of elution of agent from the stent, either mural or luminal. FIGS. 3-11 are merely illustrative of some of the concentration gradients which are useful. Further combinations of two or more agents with independent concentration gradients can provide a range of controlled release kinetic profiles of the agents from the matrix in or on the stent.
THERAPEUTIC AGENTS
[0051] Other therapeutic agents for use with the present invention may, for example, take the form of small molecules, peptides, lipoproteins, polypeptides, polynucleotides encoding polypeptides, lipids, protein-drugs, protein conjugate drugs, enzymes, oligonucleotides and their derivatives, ribozymes, other genetic material, cells, antisense oligonucleotides, monoclonal antibodies, platelets, prions, viruses, bacteria, eukaryotic cells such as endothelial cells, stem cells, ACE
inhibitors, monocyte/macrophages and vascular smooth muscle cells. Such agents can be used alone or in various combinations with one another. For instance, anti-inflammatories may be used in combination with antiproliferatives to mitigate the reaction of tissue to the antiproliferative. The therapeutic agent may also be a pro-drug, which metabolizes into the desired drug when administered to a host. In addition, therapeutic agents maybe pre-formulated as microcapsules, microspheres, microbubbles, liposomes, niosomes, emulsions, dispersions or the like before they are incorporated into the matrix. Therapeutic agents may also be radioactive isotopes or agents activated by some other form of energy such as light or ultrasonic energy, or by other circulating molecules that can be systemically administered.
[0052] Exemplary classes of therapeutic agents include antiproliferatives, antithrombins (i.e., thrombolytics), immunosuppressants, antilipid agents, anti-inflammatory agents, antineoplastics including antimetabolites, antiplatelets, angiogenic agents, anti-angiogenic agents, vitamins, antimitotics, metalloproteinase inhibitors, NO donors, nitric oxide release stimulators, anti-sclerosing agents, vasoactive agents, endothelial growth factors, beta blockers, AZ blockers, hormones, statins, insulin growth factors, antioxidants, membrane stabilizing agents, calcium antagonists (i.e., calcium channel antagonists), retinoids, anti-macrophage substances, antilymphocytes, cyclooxygenase inhibitors, immunomodulatory agents, angiotensin converting enzyme (ACE) inhibitors, anti-leukocytes, high-density lipoproteins (HDL) and derivatives, cell sensitizers to insulin, prostaglandin and derivatives, anti-TNF compounds, hypertension drugs, protein kinases, antisense oligonucleotides, cardio protectants, petidose inhibitors (increase blycolitic metabolism), endothelin receptor agonists, interleukin-6 antagonists, anti-restenotics, and other miscellaneous compounds.
[00531 Antiproliferatives include, without limitation, sirolimus, paclitaxel, actinomycin D, rapamycin, and cyclosporin.
[00541 Antithrombins include, without limitation, heparin, plasminogen, x2-antiplasmin, streptokinase, bivalirudin, and tissue plasminogen activator (t-PA).
[00551 Immunosuppressants include, without limitation, cyclosporine, rapamycin and tacrolimus (FTC-506), sirolumus, everolimus, etoposide, and mitoxantrone.
[00561 Antilipid agents include, without limitation, }Th'IG CoA reductase inhibitors, nicotinic acid, probucol, and fibric acid derivatives (e.g., clofibrate, gemfibrozil, gemfibrozil, fenofibrate, ciprofibrate, and bezafibrate).
[00571 Anti-inflammatory agents include, without limitation, salicylic acid derivatives (e.g., aspirin, insulin, sodium salicylate, choline magnesium trisalicylate, salsalate, dflunisal, salicylsalicylic acid, sulfasalazine, and olsalazine), para-amino phenol derivatives (e.g., acetaminophen), indole and indene acetic acids (e.g., indomethacin, sulindac, and etodolac), heteroaryl acetic acids (e.g., tolmetin, diclofenac, and ketorolac), arylpropionic acids (e.g., ibuprofen, naproxen, flurbiprofen, ketoprofen, fenoprofen, and oxaprozin), anthranilic acids (e.g., mefenamic acid and meclofenamic acid), enolic acids (e.g., piroxicam, tenoxicam, phenylbutazone and oxyphenthatrazone), alkanones (e.g., nabumetone), glucocorticoids (e.g., dexamethaxone, prednisolone, and triamcinolone), pirfenidone, and tranilast.
[0041] The therapeutic agent containing matrix can be disposed in the stent or on surfaces of the stent in various configurations, including within volumes defined by the stent, such as openings, holes, or concave surfaces, as a reservoir of agent, and alternatively as a coating on all or a portion of surfaces of the stent structure.
When the therapeutic agent matrix is disposed within openings in the strut structure of the stent to form a reservoir, the openings may be partially or completely filled with matrix containing the therapeutic agent.
[0042] The concentration of agent in a local region of the matrix is the sum of the amount of agent dissolved in the matrix, in a so-called solid solution morphology, and the amount dispersed in that local region of the matrix, a so-called solid emulsion morphology. The relative amount of dissolved and dispersed agent in a region is controlled by the solubility of the agent in the matrix material. When the limit of solubility of the agent in the matrix material is reached, any additional agent will be in a dispersed second phase particulate morphology.
[0043] FIG. 3 is a cross section of the stent 10 and blood vessel 100 illustrating one example of an opening 14 arranged adjacent the vessel wall with a mural surface 26 abutting the vessel wall and a luminal surface 24 opposite the mural surface. The opening 14 of FIG. 3 contains a matrix 40 with a therapeutic agent illustrated by Os in the matrix. As can be seen in the example of FIG. 3, the concentration of the therapeutic agent (Os) is highest at the luminal side of the matrix 40 and lowest at the mural side of the matrix. The luminal side 24 of the stent 10 is also provided with a barrier layer 30. The barrier layer 30 causes the therapeutic agent to be delivered primarily to the mural side 26 of the stent.
[0044] FIG. 4 illustrates graphically a concentration gradient similar to that depicted in FIG. 3 where the agent concentration in the matrix is highest in the middle of the stent or adjacent the luminally located barrier layer 30 and the agent concentration decreases moving toward the mural side of the matrix. The concentration gradient is described by the local concentration of the agent in matrix regions along a theoretical line substantially perpendicular to the surfaces of the matrix. A continuous agent concentration gradient is where the agent concentration in a volume of matrix varies in a blended fashion in moving between successive positions along the line substantially perpendicular to the matrix surface.
Thus, if the matrix surface was substantially collinear with the stent surface and the matrix was sliced into a plurality of slices substantially parallel to the stent surface, the adjacent slices will have different agent concentrations. Alternately, the matrix surface maybe contoured and the adjacent slices maybe similarly configured.
[0045] As illustrated in FIG. 3, the barrier layer 30 includes no therapeutic agent and the concentration gradient of therapeutic agent is provided in the matrix in the portion of the opening 14 not containing the barrier material. Alternatively, the barrier layer 30 may include some therapeutic agent and the concentration gradient may continue in part or all of the barrier layer.
[0046] As shown in FIG. 4, the change in agent concentration in the matrix is a continuous function of the position relative to the matrix surfaces. As shown in FIG.
5, the release kinetics of the system of FIGS. 3 and 4 can be essentially linear (essentially constant release rate over time) after an initial release. Such substantially linear release profiles are described in further detail in U.S.
Patent Publication No. 2004 /0204756 filed on February 11, 2004.
[0047] FIG. 6 illustrates a configuration of a matrix 50 in an opening 14 where the matrix and therapeutic agent concentration gradient are designed for rapid initial release of agent to the luminal side followed by a low level release for an extended time. The agent concentration in FIG. 6 is high at the luminal surface 24 of the matrix 50 and the concentration gradient will decrease steeply in the interior of the matrix. FIG. 7 illustrates the concentration gradient of the FIG. 6 example graphically. FIG. 8 illustrates the agent release over time for the example of FIGS. 6 and 7. Using careful specification of the agent concentration gradient in this example, substantially first order agent release kinetics with directionally controlled delivery may be obtained.
[0048] Since the matrix is created in a stepwise manner, as will be described below, individual chemical compositions and pharmacokinetic properties can be imparted to different areas of the matrix. Numerous useful arrangements of such matrix areas can be formed, some of which will be described herein. Each of the areas of the matrix may include one or more agents in the same or different proportions from one area to the next. The matrix may be solid, porous, or filled with other drugs or excipients. The agents maybe homogeneously disposed or heterogeneously disposed in different areas of the matrix.
[0049] FIG. 9 illustrates an example of another stent 10 having a matrix 60 containing two agents with different concentration gradients. In FIG. 9, a first agent (Drug A) represented by Os is has a concentration gradient with a maximum concentration at a luminal side 24= of the stent. A second agent (Drug B) represented by s has a concentration gradient with a maximum concentration at a mural side of the matrix. This configuration results in the delivery of two drugs in different primary delivery directions. For example, an antithrombotic agent (Drug A) may be delivered primarily luminally at a relatively quick initial release rate while an antirestenotic agent (Drug B) is delivered primarily murally with a different delivery profile having a more constant release rate and longer administration period.
FIG.
10 illustrates graphically the agent concentration gradients of the first agent (Drug A) and the second agent (Drug B). FIG. 11 illustrates the cumulative release of the first and second agents (Drug A and Drug B) over time.
[0050] It is envisioned that the continuous agent concentration gradient will take a variety of forms depending on the desired administration period and rate of elution of the agent into the tissue surrounding the stent, as well as the desired direction of elution of agent from the stent, either mural or luminal. FIGS. 3-11 are merely illustrative of some of the concentration gradients which are useful. Further combinations of two or more agents with independent concentration gradients can provide a range of controlled release kinetic profiles of the agents from the matrix in or on the stent.
THERAPEUTIC AGENTS
[0051] Other therapeutic agents for use with the present invention may, for example, take the form of small molecules, peptides, lipoproteins, polypeptides, polynucleotides encoding polypeptides, lipids, protein-drugs, protein conjugate drugs, enzymes, oligonucleotides and their derivatives, ribozymes, other genetic material, cells, antisense oligonucleotides, monoclonal antibodies, platelets, prions, viruses, bacteria, eukaryotic cells such as endothelial cells, stem cells, ACE
inhibitors, monocyte/macrophages and vascular smooth muscle cells. Such agents can be used alone or in various combinations with one another. For instance, anti-inflammatories may be used in combination with antiproliferatives to mitigate the reaction of tissue to the antiproliferative. The therapeutic agent may also be a pro-drug, which metabolizes into the desired drug when administered to a host. In addition, therapeutic agents maybe pre-formulated as microcapsules, microspheres, microbubbles, liposomes, niosomes, emulsions, dispersions or the like before they are incorporated into the matrix. Therapeutic agents may also be radioactive isotopes or agents activated by some other form of energy such as light or ultrasonic energy, or by other circulating molecules that can be systemically administered.
[0052] Exemplary classes of therapeutic agents include antiproliferatives, antithrombins (i.e., thrombolytics), immunosuppressants, antilipid agents, anti-inflammatory agents, antineoplastics including antimetabolites, antiplatelets, angiogenic agents, anti-angiogenic agents, vitamins, antimitotics, metalloproteinase inhibitors, NO donors, nitric oxide release stimulators, anti-sclerosing agents, vasoactive agents, endothelial growth factors, beta blockers, AZ blockers, hormones, statins, insulin growth factors, antioxidants, membrane stabilizing agents, calcium antagonists (i.e., calcium channel antagonists), retinoids, anti-macrophage substances, antilymphocytes, cyclooxygenase inhibitors, immunomodulatory agents, angiotensin converting enzyme (ACE) inhibitors, anti-leukocytes, high-density lipoproteins (HDL) and derivatives, cell sensitizers to insulin, prostaglandin and derivatives, anti-TNF compounds, hypertension drugs, protein kinases, antisense oligonucleotides, cardio protectants, petidose inhibitors (increase blycolitic metabolism), endothelin receptor agonists, interleukin-6 antagonists, anti-restenotics, and other miscellaneous compounds.
[00531 Antiproliferatives include, without limitation, sirolimus, paclitaxel, actinomycin D, rapamycin, and cyclosporin.
[00541 Antithrombins include, without limitation, heparin, plasminogen, x2-antiplasmin, streptokinase, bivalirudin, and tissue plasminogen activator (t-PA).
[00551 Immunosuppressants include, without limitation, cyclosporine, rapamycin and tacrolimus (FTC-506), sirolumus, everolimus, etoposide, and mitoxantrone.
[00561 Antilipid agents include, without limitation, }Th'IG CoA reductase inhibitors, nicotinic acid, probucol, and fibric acid derivatives (e.g., clofibrate, gemfibrozil, gemfibrozil, fenofibrate, ciprofibrate, and bezafibrate).
[00571 Anti-inflammatory agents include, without limitation, salicylic acid derivatives (e.g., aspirin, insulin, sodium salicylate, choline magnesium trisalicylate, salsalate, dflunisal, salicylsalicylic acid, sulfasalazine, and olsalazine), para-amino phenol derivatives (e.g., acetaminophen), indole and indene acetic acids (e.g., indomethacin, sulindac, and etodolac), heteroaryl acetic acids (e.g., tolmetin, diclofenac, and ketorolac), arylpropionic acids (e.g., ibuprofen, naproxen, flurbiprofen, ketoprofen, fenoprofen, and oxaprozin), anthranilic acids (e.g., mefenamic acid and meclofenamic acid), enolic acids (e.g., piroxicam, tenoxicam, phenylbutazone and oxyphenthatrazone), alkanones (e.g., nabumetone), glucocorticoids (e.g., dexamethaxone, prednisolone, and triamcinolone), pirfenidone, and tranilast.
[0058] Antineoplastics include, without limitation, nitrogen mustards (e.g., mechlorethamine, cyclophosphamide, ifosfamide, melphalan, and chlorambucil), methylnitrosoureas (e.g., streptozocin), 2-chloroethylnitrosoureas (e.g., carmustine, lomustine, semustine, and chlorozotocin), alkanesulfonic acids (e.g., busulfan), ethylenimines and methylmelamines (e.g., triethylenemelamine, thiotepa and altretamine), triazines (e.g., dacarbazine), folic acid analogs (e.g., methotrexate), pyrimidine analogs (5-fluorouracil, 5-fluorodeoxyuridine, 5-fluorodeoxyuridine monophosphate, cytosine arabinoside, 5-azacytidine, and 2',2'-difluorodeoxycytidine), purine analogs (e.g., mercaptopurine, thioguanine, azathioprine, adenosine, pentostatin, cladribine, and erythrohydroxynonyladenine), antimitotic drugs (e.g., vinblastine, vincristine, vindesine, vinorelbine, paclitaxel, docetaxel, epipodophyllotoxins, dactinomycin, daunorubicin, doxorubicin, idarubicin, epirubicin, mitoxantrone, bleomycins, plicamycin and mitomycin), phenoxodiol, etoposide, and platinum coordination complexes (e.g., cisplatin and carboplatin).
[0059] Antiplatelets include, without limitation, insulin, dipyridamole, tirofiban, eptifibatide, abciximab, and ticlopidine.
[0060] Angiogenic agents include, without limitation, phospholipids, ceramides, cerebrosides, neutral lipids, triglycerides, diglycerides, monoglycerides lecithin, sphingosides, angiotensin fragments, nicotine, pyruvate tliiolesters, glycerol-pyruvate esters, dihydoxyacetone-pyruvate esters and monobutyrin.
[0061] Anti-angiogenic agents include, without limitation, endostatin, angiostatin, fumagillin and ovalicin.
[0062] Vitamins include, without limitation, water-soluble vitamins (e.g., thiamin, nicotinic acid, pyridoxine, and ascorbic acid) and fat-soluble vitamins (e.g., retinal, retinoic acid, retinaldehyde, phytonadione, menaqinone, menadione, and alpha tocopherol).
[0059] Antiplatelets include, without limitation, insulin, dipyridamole, tirofiban, eptifibatide, abciximab, and ticlopidine.
[0060] Angiogenic agents include, without limitation, phospholipids, ceramides, cerebrosides, neutral lipids, triglycerides, diglycerides, monoglycerides lecithin, sphingosides, angiotensin fragments, nicotine, pyruvate tliiolesters, glycerol-pyruvate esters, dihydoxyacetone-pyruvate esters and monobutyrin.
[0061] Anti-angiogenic agents include, without limitation, endostatin, angiostatin, fumagillin and ovalicin.
[0062] Vitamins include, without limitation, water-soluble vitamins (e.g., thiamin, nicotinic acid, pyridoxine, and ascorbic acid) and fat-soluble vitamins (e.g., retinal, retinoic acid, retinaldehyde, phytonadione, menaqinone, menadione, and alpha tocopherol).
[0063] Antimitotics include, without limitation, vinblastine, vincristine, vindesine, vinorelbine, paclitaxel, docetaxel, epipodophyllotoxins, dactinomycin, daunorubicin, doxorubicin, idarubicin, epirubicin, mitoxantrone, bleomycins, plicamycin and mitomycin.
[0064] Metalloproteinase inhibitors include, without limitation, TEMP-1, TIMP-2, TIMP-3, and SmaPI.
[0065] NO donors include, without limitation, L-arginine, amyl nitrite, glyceryl trinitrate, sodium nitroprusside, molsidomine, diazeniumdiolates, S-nitrosothiols, and mesoionic oxatriazole derivatives.
[0066] NO release stimulators include, without limitation, adenosine.
[0067] Anti-sclerosing agents include, without limitation, collagenases and halofuginone.
[0063] Vasoactive agents include, without limitation, nitric oxide, adenosine, nitroglycerine, sodium nitroprusside, hydralazine, phentolamine, methoxamine, metaraminol, ephedrine, trapadil, dipyridamole, vasoactive intestinal polypeptides (VIP), arginine, and vasopressin.
[0069] Endothelial growth factors include, without limitation, VEGF (Vascular Endothelial Growth Factor) including VEGF-121 and VEG-165, FGF (Fibroblast Growth Factor) including FGF-1 and FGF-2, HGF (Hepatocyte Growth Factor), and Angl (Angiopoietin 1).
[0070] Beta blockers include, without limitation, propranolol, nadolol, timolol, pindolol, labetalol, metoprolol, atenolol, esmolol, and acebutolol.
[0071] Hormones include, without limitation, progestin, insulin, the estrogens and estradiols (e.g., estradiol, estradiol valerate, estradiol cypionate, ethinyl estradiol, mestranol, quinestrol, estrond, estrone sulfate, and equilin).
[0064] Metalloproteinase inhibitors include, without limitation, TEMP-1, TIMP-2, TIMP-3, and SmaPI.
[0065] NO donors include, without limitation, L-arginine, amyl nitrite, glyceryl trinitrate, sodium nitroprusside, molsidomine, diazeniumdiolates, S-nitrosothiols, and mesoionic oxatriazole derivatives.
[0066] NO release stimulators include, without limitation, adenosine.
[0067] Anti-sclerosing agents include, without limitation, collagenases and halofuginone.
[0063] Vasoactive agents include, without limitation, nitric oxide, adenosine, nitroglycerine, sodium nitroprusside, hydralazine, phentolamine, methoxamine, metaraminol, ephedrine, trapadil, dipyridamole, vasoactive intestinal polypeptides (VIP), arginine, and vasopressin.
[0069] Endothelial growth factors include, without limitation, VEGF (Vascular Endothelial Growth Factor) including VEGF-121 and VEG-165, FGF (Fibroblast Growth Factor) including FGF-1 and FGF-2, HGF (Hepatocyte Growth Factor), and Angl (Angiopoietin 1).
[0070] Beta blockers include, without limitation, propranolol, nadolol, timolol, pindolol, labetalol, metoprolol, atenolol, esmolol, and acebutolol.
[0071] Hormones include, without limitation, progestin, insulin, the estrogens and estradiols (e.g., estradiol, estradiol valerate, estradiol cypionate, ethinyl estradiol, mestranol, quinestrol, estrond, estrone sulfate, and equilin).
[0072] Statins include, without limitation, mevastatin, lovastatin, simvastatin, pravastatin, atorvastatin, and fluvastatin.
[0073] Insulin growth factors include, without limitation, IGF-1 and IGF-2.
[0074] Antioxidants include, without limitation, vitamin A, carotenoids and vitamin E.
[0075] Membrane stabilizing agents include, without limitation, certain beta blockers such as propranolol, acebutolol, labetalol, oxprenolol, pindolol and alprenolol.
[0076] Calcium antagonists include, without limitation, amlodipine, bepridil, diltiazem, felodipine, isradipine, nicardipine, nifedipine, nimodipine and verapamil.
[0077] Retinoids include, without limitation, all-trans-retinol, all-trans-14-hydroxyretroretinol, all-trans-retinaldehyde, all-trans-retinoic acid, all-trans-3,4-didehydroretinoic acid, 9-cis-retinoic acid, 11-cis-retinal, 13-cis-retinal, and 13-cis-retinoic acid.
[0078] Anti-macrophage substances include, without limitation, NO donors.
[0079] Anti-leukocytes include, without limitation, 2-CdA, IL-1 inhibitors, anti-CD 1 16/CD 18 monoclonal antibodies, monoclonal antibodies to VCAM, monoclonal antibodies to ICAM, and zinc protoporphyrin.
[0080] Cyclooxygenase inhibitors include, without limitation, Cox-1 inhibitors and Cox-2 inhibitors (e.g., CELEEREX and VIOXX ).
[0081] Immunomodulatory agents include, without limitation, immunosuppressants (see above) and immunostimulants (e.g., levamisole, isoprinosine, Interferon alpha, and Interleukin-2).
[0082] ACE inhibitors include, without limitation, benazepril, captopril, enalapril, fosinopril sodium, lisinopril, quinapril, ramipril, and spirapril.
[0073] Insulin growth factors include, without limitation, IGF-1 and IGF-2.
[0074] Antioxidants include, without limitation, vitamin A, carotenoids and vitamin E.
[0075] Membrane stabilizing agents include, without limitation, certain beta blockers such as propranolol, acebutolol, labetalol, oxprenolol, pindolol and alprenolol.
[0076] Calcium antagonists include, without limitation, amlodipine, bepridil, diltiazem, felodipine, isradipine, nicardipine, nifedipine, nimodipine and verapamil.
[0077] Retinoids include, without limitation, all-trans-retinol, all-trans-14-hydroxyretroretinol, all-trans-retinaldehyde, all-trans-retinoic acid, all-trans-3,4-didehydroretinoic acid, 9-cis-retinoic acid, 11-cis-retinal, 13-cis-retinal, and 13-cis-retinoic acid.
[0078] Anti-macrophage substances include, without limitation, NO donors.
[0079] Anti-leukocytes include, without limitation, 2-CdA, IL-1 inhibitors, anti-CD 1 16/CD 18 monoclonal antibodies, monoclonal antibodies to VCAM, monoclonal antibodies to ICAM, and zinc protoporphyrin.
[0080] Cyclooxygenase inhibitors include, without limitation, Cox-1 inhibitors and Cox-2 inhibitors (e.g., CELEEREX and VIOXX ).
[0081] Immunomodulatory agents include, without limitation, immunosuppressants (see above) and immunostimulants (e.g., levamisole, isoprinosine, Interferon alpha, and Interleukin-2).
[0082] ACE inhibitors include, without limitation, benazepril, captopril, enalapril, fosinopril sodium, lisinopril, quinapril, ramipril, and spirapril.
[0083] Cell sensitizers to insulin include, without limitation, glitazones, P
par agonists and metformin.
[0084] Antisense oligonucleotides include, without limitation, resten-NG.
[0085] Cardio protectants include, without limitation, VIP, pituitary adenylate cyclase-activating peptide (PACAP), apoA-I milano, amlodipine, nicorandil, cilostaxone, and thienopyridine.
[0086] Petidose inhibitors include, without limitation, omnipatrilat.
[0087] Anti-restenotics include, without limitation, include vincristine, vinblastine, actinomycin, epothilone, paclitaxel, and paclitaxel derivatives (e.g., docetaxel).
[0088] Miscellaneous compounds include, without limitation, Adiponectin.
[0089] Agents may also be delivered using a gene therapy-based approach in combination with an expandable medical device. Gene therapy refers to the delivery of exogenous genes to a cell or tissue, thereby causing target cells to express the exogenous gene product. Genes are typically delivered by either mechanical or vector-mediated methods.
[0090] Some of the agents described herein may be combined with additives which preserve their activity. For example additives including surfactants, antacids, antioxidants, and detergents may be used to minimize denaturation and aggregation of a protein drug. Anionic, cationic, or nonionic detergents may be used.
Examples of nonionic additives include but are not limited to sugars including sorbitol, sucrose, trehalose; dextrans including dextran, carboxy methyl (CM) dextran, diethylamino ethyl (DEAE) dextran; sugar derivatives including D-glucosaminic acid, and D-glucose diethyl mercaptal; synthetic polyethers including polyethylene glycol (PEG and PEO) and polyvinyl pyrrolidone (PVP); carboxylic acids including D-lactic acid, glycolic acid, and propionic acid; detergents with affinity for hydrophobic interfaces including n-dodecyl-(3-D-maltoside, n-octyl-(3-D-glucoside, PEO-fatty acid esters (e.g. stearate (myrj 59) or oleate), PEO-sorbitan-fatty acid esters (e.g. Tween 80, PEO-20 sorbitan monooleate), sorbitan-fatty acid esters (e.g.
SPAN 60, sorbitan monostearate), PEO-glyceryl-fatty acid esters; glyceryl fatty acid esters (e.g. glyceryl monostearate), PEO-hydrocarbon-ethers (e.g. PEO-10 oleyl ether; triton X-100; and Lubrol. Examples of ionic detergents include but are not limited to fatty acid salts including calcium stearate, magnesium stearate, and zinc stearate; phospholipids including lecithin and phosphatidyl choline; CM-PEG;
cholic acid; sodium dodecyl sulfate (SDS); docusate (AOT); and taumocholic acid.
1o MATRIX FORMATION METHODS
[0091] The agent matrix structure with the agent concentration gradient can be formed by several methods. According to one method, agent and polymer material are together converted into agent matrix reservoirs with an agent concentration gradient structure by first creating a homogeneous solution of agent and polymer carrier in a liquid form, such as in a solvent. One example of a solvent is one in which all agent and polymer are fully soluble at the respective concentrations desired for processing such that all ingredients are molecularly dissolved in the solvent.
[0092] Solvents may be water based, as when water soluble agents and water soluble polymers are the components of the agent delivery matrix.
Alternatively, solvents can be mixtures of water with miscible organic solvents, such as dimethyl sulfoxide (DMSO), Nmethyl pyrrolidone (NMP), ethyl lactate (EL), dimethyl acetamide (DMAc), or simple alcohols. Additionally, non-aqueous solvents, predominantly organic solvents, can be suitable for non-water soluble polymers, such as poly(lactide-co-glycolide) polymers (PLGAs). Example organic solvents include DMSO, NMP, EL, anisole, chloroform, tetrahydrofuran (THF), xylene, and methylene chloride.
par agonists and metformin.
[0084] Antisense oligonucleotides include, without limitation, resten-NG.
[0085] Cardio protectants include, without limitation, VIP, pituitary adenylate cyclase-activating peptide (PACAP), apoA-I milano, amlodipine, nicorandil, cilostaxone, and thienopyridine.
[0086] Petidose inhibitors include, without limitation, omnipatrilat.
[0087] Anti-restenotics include, without limitation, include vincristine, vinblastine, actinomycin, epothilone, paclitaxel, and paclitaxel derivatives (e.g., docetaxel).
[0088] Miscellaneous compounds include, without limitation, Adiponectin.
[0089] Agents may also be delivered using a gene therapy-based approach in combination with an expandable medical device. Gene therapy refers to the delivery of exogenous genes to a cell or tissue, thereby causing target cells to express the exogenous gene product. Genes are typically delivered by either mechanical or vector-mediated methods.
[0090] Some of the agents described herein may be combined with additives which preserve their activity. For example additives including surfactants, antacids, antioxidants, and detergents may be used to minimize denaturation and aggregation of a protein drug. Anionic, cationic, or nonionic detergents may be used.
Examples of nonionic additives include but are not limited to sugars including sorbitol, sucrose, trehalose; dextrans including dextran, carboxy methyl (CM) dextran, diethylamino ethyl (DEAE) dextran; sugar derivatives including D-glucosaminic acid, and D-glucose diethyl mercaptal; synthetic polyethers including polyethylene glycol (PEG and PEO) and polyvinyl pyrrolidone (PVP); carboxylic acids including D-lactic acid, glycolic acid, and propionic acid; detergents with affinity for hydrophobic interfaces including n-dodecyl-(3-D-maltoside, n-octyl-(3-D-glucoside, PEO-fatty acid esters (e.g. stearate (myrj 59) or oleate), PEO-sorbitan-fatty acid esters (e.g. Tween 80, PEO-20 sorbitan monooleate), sorbitan-fatty acid esters (e.g.
SPAN 60, sorbitan monostearate), PEO-glyceryl-fatty acid esters; glyceryl fatty acid esters (e.g. glyceryl monostearate), PEO-hydrocarbon-ethers (e.g. PEO-10 oleyl ether; triton X-100; and Lubrol. Examples of ionic detergents include but are not limited to fatty acid salts including calcium stearate, magnesium stearate, and zinc stearate; phospholipids including lecithin and phosphatidyl choline; CM-PEG;
cholic acid; sodium dodecyl sulfate (SDS); docusate (AOT); and taumocholic acid.
1o MATRIX FORMATION METHODS
[0091] The agent matrix structure with the agent concentration gradient can be formed by several methods. According to one method, agent and polymer material are together converted into agent matrix reservoirs with an agent concentration gradient structure by first creating a homogeneous solution of agent and polymer carrier in a liquid form, such as in a solvent. One example of a solvent is one in which all agent and polymer are fully soluble at the respective concentrations desired for processing such that all ingredients are molecularly dissolved in the solvent.
[0092] Solvents may be water based, as when water soluble agents and water soluble polymers are the components of the agent delivery matrix.
Alternatively, solvents can be mixtures of water with miscible organic solvents, such as dimethyl sulfoxide (DMSO), Nmethyl pyrrolidone (NMP), ethyl lactate (EL), dimethyl acetamide (DMAc), or simple alcohols. Additionally, non-aqueous solvents, predominantly organic solvents, can be suitable for non-water soluble polymers, such as poly(lactide-co-glycolide) polymers (PLGAs). Example organic solvents include DMSO, NMP, EL, anisole, chloroform, tetrahydrofuran (THF), xylene, and methylene chloride.
[0093] In the first method, steps (i) and (ii) are preformed followed by steps (iii) and (iv) which are repeated until the desired concentration gradient structure is obtained:
i) a solution comprised of suitable solvent and polymer material, and optionally a therapeutic agent, is introduced into an opening on the stent;
ii) the solvent is evaporated from the solution to form a first portion of matrix;
iii) a second solution is introduced which partially dissolves of otherwise liquifies the precedent material from step (ii) and allows partial mixing of the agent of precedent material and the components of the second solution to create a new hybrid solution in the cavity or hole in the stent; and iv) the solvent is evaporated from the newly formed hybrid solution to provide a portion of matrix having a concentration gradient of the agent therein.
By changing the composition of successive solutions there will result a final agent containing matrix where the agent is present in a continuously changing concentration relative to the depth of the matrix, termed a concentration gradient.
[0094] Although the process has been described employing a solvent, a similar process may use a solution without a solvent when the polymer is heated to achieve a liquefied or flowable condition.
[0095] Two general sequences of solution compositions can provide the concentration gradient structure of the invention. In a first sequence, one or several iterations of the same agent and polymer compositions are introduced as described followed by successive iterations of solutions containing polymer only. In this manner a first portion of matrix is fabricated with an agent containing solution followed by introduction of a second portion of matrix without agent. The second portion of matrix without the agent introduced just after the first portion containing agent will extract a portion of agent from the first portion into itself, creating a concentration gradient of the agent in the combined structure after the solvent has evaporated. Successive additions of solutions with polymer and no agent will only be able to dissolve the portion formed just before, which has successively smaller amounts of agent, so as the depth of the matrix is increased by successive additions the agent proportion will be successively decreasing, continuing the formation of an agent concentration gradient.
[0096] Although the first method has been described with reference to depositing in a hole or cavity, the matrix may also be formed on the stent or in the stent in other configurations including coatings or partial coatings in substantially the same manner. Coatings are generally less preferable than reservoirs, as the depth of reservoirs permits more complex morphologies.
[0097] In a second sequence, a first series of iterations are done with a solution containing matrix and an agent at a first agent concentration, followed by a second series of iterations done with a solution having matrix and the agent at a second agent concentration. The resultant matrix will have a agent concentration gradient where the absolute concentration is near the first concentration at one side of the matrix, at an intermediate concentration in the middle of the matrix, and near the second agent concentration at the opposite side of the matrix.
[0098] In a second method an agent concentration gradient is formed in the matrix by a process of diffusion. A matrix containing no agent is first prepared from solutions containing polymer. The forined matrix is then immersed in a solution containing an agent for a time period to allow a partial diffusion of the agent from the solution into the matrix, then the matrix is removed from the solution.
The resultant matrix will have a relatively higher agent concentration near the surface(s) that contacted the solution and lower concentration toward the opposite side, thus forming an agent concentration gradient across the depth of the agent containing matrix.
i) a solution comprised of suitable solvent and polymer material, and optionally a therapeutic agent, is introduced into an opening on the stent;
ii) the solvent is evaporated from the solution to form a first portion of matrix;
iii) a second solution is introduced which partially dissolves of otherwise liquifies the precedent material from step (ii) and allows partial mixing of the agent of precedent material and the components of the second solution to create a new hybrid solution in the cavity or hole in the stent; and iv) the solvent is evaporated from the newly formed hybrid solution to provide a portion of matrix having a concentration gradient of the agent therein.
By changing the composition of successive solutions there will result a final agent containing matrix where the agent is present in a continuously changing concentration relative to the depth of the matrix, termed a concentration gradient.
[0094] Although the process has been described employing a solvent, a similar process may use a solution without a solvent when the polymer is heated to achieve a liquefied or flowable condition.
[0095] Two general sequences of solution compositions can provide the concentration gradient structure of the invention. In a first sequence, one or several iterations of the same agent and polymer compositions are introduced as described followed by successive iterations of solutions containing polymer only. In this manner a first portion of matrix is fabricated with an agent containing solution followed by introduction of a second portion of matrix without agent. The second portion of matrix without the agent introduced just after the first portion containing agent will extract a portion of agent from the first portion into itself, creating a concentration gradient of the agent in the combined structure after the solvent has evaporated. Successive additions of solutions with polymer and no agent will only be able to dissolve the portion formed just before, which has successively smaller amounts of agent, so as the depth of the matrix is increased by successive additions the agent proportion will be successively decreasing, continuing the formation of an agent concentration gradient.
[0096] Although the first method has been described with reference to depositing in a hole or cavity, the matrix may also be formed on the stent or in the stent in other configurations including coatings or partial coatings in substantially the same manner. Coatings are generally less preferable than reservoirs, as the depth of reservoirs permits more complex morphologies.
[0097] In a second sequence, a first series of iterations are done with a solution containing matrix and an agent at a first agent concentration, followed by a second series of iterations done with a solution having matrix and the agent at a second agent concentration. The resultant matrix will have a agent concentration gradient where the absolute concentration is near the first concentration at one side of the matrix, at an intermediate concentration in the middle of the matrix, and near the second agent concentration at the opposite side of the matrix.
[0098] In a second method an agent concentration gradient is formed in the matrix by a process of diffusion. A matrix containing no agent is first prepared from solutions containing polymer. The forined matrix is then immersed in a solution containing an agent for a time period to allow a partial diffusion of the agent from the solution into the matrix, then the matrix is removed from the solution.
The resultant matrix will have a relatively higher agent concentration near the surface(s) that contacted the solution and lower concentration toward the opposite side, thus forming an agent concentration gradient across the depth of the agent containing matrix.
[0099] This second method can be performed with a matrix in the form of a coating on a stent or a partial coating on a stent, with a matrix within openings in a stent, a matrix prior to placing the matrix on or in the stent, or another matrix configuration. When the matrix is formed within openings in a stent a barrier layer maybe placed on one side of the opening to allow diffusion of the agent into the matrix from primarily one side of the opening. The barrier layer may subsequently be removed if delivery from the barrier side is desired. Additional barrier layers may be added after formation of the concentration gradient if desired. The barrier layer can be a bioresorbable or non-bioresorbable.
Example 1 - Formulation comprising a Gradient of a Therapeutic Agent [00100] In the example below, the following abbreviations have the following meanings.
PLGA = poly(lactide-co-glycolide) 1s DMSO = Dimethyl sulfoxide NMP = N-methylpyrrolidone DMAC = Dimethyl acetamide [00101] A first mixture of high molecular weight PLGA and a suitable organic solvent, such as DMSO, NMP, or DMAC 93% wt. is prepared. The mixture is loaded dropwise into openings in the stent, then the solvent is evaporated to begin formation of the barrier layer. A one or more additional barrier layers are laid over the first by the same method of filling polymer solution into the hole followed by solvent evaporation.
[00102] A second mixture of paclitaxel and low molecular weight PLGA, in a suitable organic solvent, such as DMSO, is introduced into openings in the stent over the barrier layer. The solvent is evaporated to form a drug filled therapeutic agent layer. The filling and evaporation procedure is repeated until the hole is filled to about 50% of its total volume with drug in therapeutic agent layer layered on top of the barrier layer.
[00103] Multiple layers of a third solution, of low molecular weight PLGA and a suitable organic solvent, such as DMSO, are then laid down over the therapeutic agent layer to form the concentration gradient. When each of the third solution layers is loaded into the stent, a portion of the layer beneath is incorporated in the new layer. In this way the matrix is formed containing a concentration gradient of paclitaxel agent.
[00104] Following implantation of the filled stent in vivo, the paclitaxel contained within the stent is delivered slowly over a time period of about 5 to about 60 days, preferably about 10 to about 30 days. The barrier layer prevents the therapeutic agent from being delivered out the barrier layer side of openings in the stent. The barrier layer completely degrades after the administration of the paclitaxel.
[00105] While the invention has been described in detail with reference to the preferred embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made and equivalents employed, without departing from the present invention.
Example 1 - Formulation comprising a Gradient of a Therapeutic Agent [00100] In the example below, the following abbreviations have the following meanings.
PLGA = poly(lactide-co-glycolide) 1s DMSO = Dimethyl sulfoxide NMP = N-methylpyrrolidone DMAC = Dimethyl acetamide [00101] A first mixture of high molecular weight PLGA and a suitable organic solvent, such as DMSO, NMP, or DMAC 93% wt. is prepared. The mixture is loaded dropwise into openings in the stent, then the solvent is evaporated to begin formation of the barrier layer. A one or more additional barrier layers are laid over the first by the same method of filling polymer solution into the hole followed by solvent evaporation.
[00102] A second mixture of paclitaxel and low molecular weight PLGA, in a suitable organic solvent, such as DMSO, is introduced into openings in the stent over the barrier layer. The solvent is evaporated to form a drug filled therapeutic agent layer. The filling and evaporation procedure is repeated until the hole is filled to about 50% of its total volume with drug in therapeutic agent layer layered on top of the barrier layer.
[00103] Multiple layers of a third solution, of low molecular weight PLGA and a suitable organic solvent, such as DMSO, are then laid down over the therapeutic agent layer to form the concentration gradient. When each of the third solution layers is loaded into the stent, a portion of the layer beneath is incorporated in the new layer. In this way the matrix is formed containing a concentration gradient of paclitaxel agent.
[00104] Following implantation of the filled stent in vivo, the paclitaxel contained within the stent is delivered slowly over a time period of about 5 to about 60 days, preferably about 10 to about 30 days. The barrier layer prevents the therapeutic agent from being delivered out the barrier layer side of openings in the stent. The barrier layer completely degrades after the administration of the paclitaxel.
[00105] While the invention has been described in detail with reference to the preferred embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made and equivalents employed, without departing from the present invention.
Claims (6)
1. A method of forming an implantable medical device configured to release at least one therapeutic agent therefreom, wherein the therapeutic agent is disposed in a matrix affixed to a body of the implantable medical device, and wherein a concentration of the at least one therapeutic agent in the matrix varies as a continuous gradient relative to a surface of the implantable medical device body, the method comprising:
forming a homogeneous solution comprising a polymeric binder and a solvent;
evaporating the solvent in the homogeneous solution, thereby forming a matrix;
exposing the matrix to a solution comprising the therapeutic agent for a time sufficient to produce a partial diffusion of the therapeutic agent into the matrix such that the concentration of the therapeutic agent varies in the matrix; and affixing the matrix to the implantable medical device body.
forming a homogeneous solution comprising a polymeric binder and a solvent;
evaporating the solvent in the homogeneous solution, thereby forming a matrix;
exposing the matrix to a solution comprising the therapeutic agent for a time sufficient to produce a partial diffusion of the therapeutic agent into the matrix such that the concentration of the therapeutic agent varies in the matrix; and affixing the matrix to the implantable medical device body.
2. The method of Claim 1, wherein the matrix is affixed to the implantable medical device body by placing the matrix into the body prior to immersing the matrix in the solution comprising the therapeutic agent.
3. The method of Claim 1, wherein the matrix is affixed to the implantable medical device body by placing the matrix into a recess in the implantable medical device body.
4. The method of Claim 1, wherein the matrix is affixed to the implantable medical device body by placing the matrix into an opening passing through the implantable medical device body.
5. The method of Claim 1, wherein the matrix is affixed to the implantable medical device body by disposing the homogeneous solution comprising a polymeric binder and a solvent into an opening and then evaporating the solvent.
6. The method of Claim 1, wherein the matrix is affixed to the implantable medical device body by coating a surface of the implantable medical device with the matrix.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/402,893 | 2003-03-28 | ||
US10/402,893 US7056338B2 (en) | 2003-03-28 | 2003-03-28 | Therapeutic agent delivery device with controlled therapeutic agent release rates |
US10/777,283 US20050010170A1 (en) | 2004-02-11 | 2004-02-11 | Implantable medical device with beneficial agent concentration gradient |
US10/777,283 | 2004-02-11 | ||
PCT/US2004/009602 WO2004087214A1 (en) | 2003-03-28 | 2004-03-29 | Implantable medical device with beneficial agent concentration gradient |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2519711A1 CA2519711A1 (en) | 2004-10-14 |
CA2519711C true CA2519711C (en) | 2012-01-17 |
Family
ID=33134802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2519711A Expired - Fee Related CA2519711C (en) | 2003-03-28 | 2004-03-29 | Implantable medical device with beneficial agent concentration gradient |
Country Status (7)
Country | Link |
---|---|
US (2) | US8449901B2 (en) |
EP (3) | EP1610823B1 (en) |
JP (1) | JP5596896B2 (en) |
AT (1) | ATE526038T1 (en) |
AU (1) | AU2004226327A1 (en) |
CA (1) | CA2519711C (en) |
WO (1) | WO2004087214A1 (en) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7169178B1 (en) * | 2002-11-12 | 2007-01-30 | Advanced Cardiovascular Systems, Inc. | Stent with drug coating |
WO2005068020A1 (en) | 2004-01-02 | 2005-07-28 | Advanced Cardiovascular Systems, Inc. | High-density lipoprotein coated medical devices |
US20060246109A1 (en) * | 2005-04-29 | 2006-11-02 | Hossainy Syed F | Concentration gradient profiles for control of agent release rates from polymer matrices |
US8568764B2 (en) | 2006-05-31 | 2013-10-29 | Advanced Cardiovascular Systems, Inc. | Methods of forming coating layers for medical devices utilizing flash vaporization |
US8246973B2 (en) | 2006-06-21 | 2012-08-21 | Advanced Cardiovascular Systems, Inc. | Freeze-thaw method for modifying stent coating |
US20080015494A1 (en) * | 2006-07-11 | 2008-01-17 | Microchips, Inc. | Multi-reservoir pump device for dialysis, biosensing, or delivery of substances |
US7682388B2 (en) * | 2007-01-30 | 2010-03-23 | Medtronic Vascular, Inc. | Stent with longitudinal groove |
WO2008098418A1 (en) * | 2007-02-14 | 2008-08-21 | Shandong Intech Medical Technology Co., Ltd. | Intracoronary stent with asymmetric drug releasing controlled coating |
JP2008245699A (en) * | 2007-03-29 | 2008-10-16 | Yamaguchi Univ | Stent for gradually releasing drug |
US8852620B2 (en) * | 2007-07-20 | 2014-10-07 | Medtronic Vascular, Inc. | Medical devices comprising polymeric drug delivery systems with drug solubility gradients |
JP2009247506A (en) * | 2008-04-03 | 2009-10-29 | Kaneka Corp | Stent |
US8652506B2 (en) * | 2008-06-05 | 2014-02-18 | Boston Scientific Scimed, Inc. | Bio-degradable block co-polymers for controlled release |
US20100249854A1 (en) * | 2009-03-31 | 2010-09-30 | Thomas Jonathan D | Multizone Implants |
US9592043B2 (en) * | 2009-03-31 | 2017-03-14 | Covidien Lp | Multizone implants |
US20100249944A1 (en) * | 2009-03-31 | 2010-09-30 | Thomas Jonathan D | Multizone Implants |
US20100249832A1 (en) * | 2009-03-31 | 2010-09-30 | Joshua Stopek | Multizone Implants |
US20100292777A1 (en) * | 2009-05-13 | 2010-11-18 | Boston Scientific Scimed, Inc. | Stent |
US9283305B2 (en) | 2009-07-09 | 2016-03-15 | Medtronic Vascular, Inc. | Hollow tubular drug eluting medical devices |
US8678046B2 (en) | 2009-09-20 | 2014-03-25 | Medtronic Vascular, Inc. | Apparatus and methods for loading a drug eluting medical device |
US8828474B2 (en) | 2009-09-20 | 2014-09-09 | Medtronic Vascular, Inc. | Apparatus and methods for loading a drug eluting medical device |
US8381774B2 (en) * | 2009-09-20 | 2013-02-26 | Medtronic Vascular, Inc. | Methods for loading a drug eluting medical device |
US20110070358A1 (en) * | 2009-09-20 | 2011-03-24 | Medtronic Vascular, Inc. | Method of forming hollow tubular drug eluting medical devices |
US8333801B2 (en) | 2010-09-17 | 2012-12-18 | Medtronic Vascular, Inc. | Method of Forming a Drug-Eluting Medical Device |
US8616040B2 (en) | 2010-09-17 | 2013-12-31 | Medtronic Vascular, Inc. | Method of forming a drug-eluting medical device |
US8632846B2 (en) | 2010-09-17 | 2014-01-21 | Medtronic Vascular, Inc. | Apparatus and methods for loading a drug eluting medical device |
DE102011107109A1 (en) * | 2011-07-12 | 2013-01-17 | Translumina Gmbh | Implantable vascular support |
US20130103162A1 (en) * | 2011-10-25 | 2013-04-25 | Kieran Costello | Coated stent |
US9220759B2 (en) | 2012-02-23 | 2015-12-29 | Abbott Cardiovascular Systems Inc. | Treatment of diabetic patients with a drug eluting stent and adjunctive therapy |
US20130259921A1 (en) * | 2012-03-30 | 2013-10-03 | Abbott Cardiovascular Systems Inc. | Treatment Of Diabetic Patients With A Stent And An Adjunctive Drug Formulation |
US9220584B2 (en) | 2012-03-30 | 2015-12-29 | Abbott Cardiovascular Systems Inc. | Treatment of diabetic patients with a stent and locally administered adjunctive therapy |
US20140099351A1 (en) | 2012-10-04 | 2014-04-10 | Axxia Pharmaceuticals, Llc | Process for making controlled release medical implant products |
US20140121750A1 (en) * | 2012-10-31 | 2014-05-01 | Cook Medical Technologies Llc | Fixation Process For Nesting Stents |
WO2014151906A1 (en) | 2013-03-14 | 2014-09-25 | Medtronic Vascular Inc. | Method for manufacturing a stent and stent manufactured thereby |
US9901663B2 (en) | 2013-05-06 | 2018-02-27 | Abbott Cardiovascular Systems Inc. | Hollow stent filled with a therapeutic agent formulation |
EP3060174B1 (en) * | 2013-10-22 | 2020-05-27 | Concievalve LLC | Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
US20160022570A1 (en) | 2014-07-25 | 2016-01-28 | Robert W. Adams | Medical implant |
Family Cites Families (429)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3657744A (en) | 1970-05-08 | 1972-04-25 | Univ Minnesota | Method for fixing prosthetic implants in a living body |
US5643314A (en) | 1995-11-13 | 1997-07-01 | Navius Corporation | Self-expanding stent |
US5876419A (en) * | 1976-10-02 | 1999-03-02 | Navius Corporation | Stent and method for making a stent |
JPS6037735B2 (en) * | 1978-10-18 | 1985-08-28 | 住友電気工業株式会社 | Artificial blood vessel |
US4300244A (en) | 1979-09-19 | 1981-11-17 | Carbomedics, Inc. | Cardiovascular grafts |
US4531936A (en) | 1981-01-29 | 1985-07-30 | Gordon Robert T | Device and method for the selective delivery of drugs to the myocardium |
US5441745A (en) | 1982-03-30 | 1995-08-15 | Vestar, Inc. | Method of delivering micellular particles encapsulating chemotherapeutic agents to tumors in a body |
US4542025A (en) | 1982-07-29 | 1985-09-17 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
US4834755A (en) | 1983-04-04 | 1989-05-30 | Pfizer Hospital Products Group, Inc. | Triaxially-braided fabric prosthesis |
US4580568A (en) | 1984-10-01 | 1986-04-08 | Cook, Incorporated | Percutaneous endovascular stent and method for insertion thereof |
US4824436A (en) | 1985-04-09 | 1989-04-25 | Harvey Wolinsky | Method for the prevention of restenosis |
US4650466A (en) * | 1985-11-01 | 1987-03-17 | Angiobrade Partners | Angioplasty device |
US4733665C2 (en) * | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US5102417A (en) | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4955878A (en) | 1986-04-04 | 1990-09-11 | Biotechnology, Inc. | Kit for preventing or treating arterial dysfunction resulting from angioplasty procedures |
JPH0763489B2 (en) | 1986-10-31 | 1995-07-12 | 宇部興産株式会社 | Medical tube |
US4800882A (en) * | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
US5059211A (en) | 1987-06-25 | 1991-10-22 | Duke University | Absorbable vascular stent |
US4969458A (en) | 1987-07-06 | 1990-11-13 | Medtronic, Inc. | Intracoronary stent and method of simultaneous angioplasty and stent implant |
US5460817A (en) | 1988-01-19 | 1995-10-24 | Allied Colloids Ltd. | Particulate composition comprising a core of matrix polymer with active ingredient distributed therein |
US5157049A (en) | 1988-03-07 | 1992-10-20 | The United States Of America As Represented By The Department Of Health & Human Services | Method of treating cancers sensitive to treatment with water soluble derivatives of taxol |
US4989601A (en) * | 1988-05-02 | 1991-02-05 | Medical Engineering & Development Institute, Inc. | Method, apparatus, and substance for treating tissue having neoplastic cells |
AU641361B2 (en) | 1988-05-02 | 1993-09-23 | Zynaxis Technologies, Incorporated | Compounds, compositions and method for binding bio-affecting substances to surface membranes of bio-particles |
US5213580A (en) | 1988-08-24 | 1993-05-25 | Endoluminal Therapeutics, Inc. | Biodegradable polymeric endoluminal sealing process |
US5019090A (en) | 1988-09-01 | 1991-05-28 | Corvita Corporation | Radially expandable endoprosthesis and the like |
US5053048A (en) | 1988-09-22 | 1991-10-01 | Cordis Corporation | Thromboresistant coating |
CA1322628C (en) * | 1988-10-04 | 1993-10-05 | Richard A. Schatz | Expandable intraluminal graft |
LU87410A1 (en) * | 1988-12-20 | 1990-07-10 | Cird | COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING POLYMERIC OR FATTY BODY MICROSPHERES CHARGED WITH AT LEAST ONE ACTIVE PRODUCT |
CH678393A5 (en) | 1989-01-26 | 1991-09-13 | Ulrich Prof Dr Med Sigwart | |
US5078726A (en) * | 1989-02-01 | 1992-01-07 | Kreamer Jeffry W | Graft stent and method of repairing blood vessels |
JPH02207940A (en) | 1989-02-06 | 1990-08-17 | Olympus Optical Co Ltd | Molding material of phosphate system |
US4960790A (en) | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
US4990155A (en) * | 1989-05-19 | 1991-02-05 | Wilkoff Howard M | Surgical stent method and apparatus |
US4994071A (en) * | 1989-05-22 | 1991-02-19 | Cordis Corporation | Bifurcating stent apparatus and method |
US5171262A (en) | 1989-06-15 | 1992-12-15 | Cordis Corporation | Non-woven endoprosthesis |
US5674278A (en) | 1989-08-24 | 1997-10-07 | Arterial Vascular Engineering, Inc. | Endovascular support device |
US5176617A (en) | 1989-12-11 | 1993-01-05 | Medical Innovative Technologies R & D Limited Partnership | Use of a stent with the capability to inhibit malignant growth in a vessel such as a biliary duct |
US5059166A (en) | 1989-12-11 | 1991-10-22 | Medical Innovative Technologies R & D Limited Partnership | Intra-arterial stent with the capability to inhibit intimal hyperplasia |
US5843089A (en) | 1990-12-28 | 1998-12-01 | Boston Scientific Corporation | Stent lining |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5439446A (en) | 1994-06-30 | 1995-08-08 | Boston Scientific Corporation | Stent and therapeutic delivery system |
US5049132A (en) | 1990-01-08 | 1991-09-17 | Cordis Corporation | Balloon catheter for delivering therapeutic agents |
US5192744A (en) | 1990-01-12 | 1993-03-09 | Northwestern University | Method of inhibiting angiogenesis of tumors |
ES2093699T3 (en) | 1990-01-25 | 1997-01-01 | Childrens Hosp Medical Center | METHOD AND COMPOSITIONS TO INHIBIT ANGIOGENESIS. |
ATE120377T1 (en) | 1990-02-08 | 1995-04-15 | Howmedica | INFLATABLE DILATATOR. |
CA2049973C (en) | 1990-02-28 | 2002-12-24 | Rodney G. Wolff | Intralumenal drug eluting prosthesis |
US5545208A (en) | 1990-02-28 | 1996-08-13 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
US5242399A (en) | 1990-04-25 | 1993-09-07 | Advanced Cardiovascular Systems, Inc. | Method and system for stent delivery |
US5344426A (en) | 1990-04-25 | 1994-09-06 | Advanced Cardiovascular Systems, Inc. | Method and system for stent delivery |
US5290271A (en) * | 1990-05-14 | 1994-03-01 | Jernberg Gary R | Surgical implant and method for controlled release of chemotherapeutic agents |
WO1991017724A1 (en) | 1990-05-17 | 1991-11-28 | Harbor Medical Devices, Inc. | Medical device polymer |
US5092841A (en) * | 1990-05-17 | 1992-03-03 | Wayne State University | Method for treating an arterial wall injured during angioplasty |
US5407683A (en) | 1990-06-01 | 1995-04-18 | Research Corporation Technologies, Inc. | Pharmaceutical solutions and emulsions containing taxol |
ATE123658T1 (en) * | 1990-06-15 | 1995-06-15 | Cortrak Medical Inc | DEVICE FOR DISPENSING MEDICATIONS. |
AU1579092A (en) | 1991-02-27 | 1992-10-06 | Nova Pharmaceutical Corporation | Anti-infective and anti-inflammatory releasing systems for medical devices |
US5171217A (en) | 1991-02-28 | 1992-12-15 | Indiana University Foundation | Method for delivery of smooth muscle cell inhibitors |
US5197978B1 (en) * | 1991-04-26 | 1996-05-28 | Advanced Coronary Tech | Removable heat-recoverable tissue supporting device |
FR2678833B1 (en) | 1991-07-08 | 1995-04-07 | Rhone Poulenc Rorer Sa | NEW PHARMACEUTICAL COMPOSITIONS BASED ON DERIVATIVES OF THE TAXANE CLASS. |
US6515009B1 (en) * | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5811447A (en) * | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5500013A (en) | 1991-10-04 | 1996-03-19 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
WO1993006792A1 (en) | 1991-10-04 | 1993-04-15 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5464450A (en) | 1991-10-04 | 1995-11-07 | Scimed Lifesystems Inc. | Biodegradable drug delivery vascular stent |
CA2380683C (en) * | 1991-10-28 | 2006-08-08 | Advanced Cardiovascular Systems, Inc. | Expandable stents and method for making same |
FR2683449A1 (en) * | 1991-11-08 | 1993-05-14 | Cardon Alain | ENDOPROTHESIS FOR TRANSLUMINAL IMPLANTATION. |
US5270047A (en) | 1991-11-21 | 1993-12-14 | Kauffman Raymond F | Local delivery of dipyridamole for the treatment of proliferative diseases |
US5260002A (en) | 1991-12-23 | 1993-11-09 | Vanderbilt University | Method and apparatus for producing uniform polymeric spheres |
US5516781A (en) | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
CA2087132A1 (en) * | 1992-01-31 | 1993-08-01 | Michael S. Williams | Stent capable of attachment within a body lumen |
DE69326631T2 (en) | 1992-03-19 | 2000-06-08 | Medtronic Inc | Intraluminal expansion device |
US5282823A (en) | 1992-03-19 | 1994-02-01 | Medtronic, Inc. | Intravascular radially expandable stent |
EP0633907A1 (en) | 1992-03-30 | 1995-01-18 | Alza Corporation | Additives for bioerodible polymers to regulate degradation |
US5383928A (en) * | 1992-06-10 | 1995-01-24 | Emory University | Stent sheath for local drug delivery |
GB9213077D0 (en) | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
DE4222380A1 (en) * | 1992-07-08 | 1994-01-13 | Ernst Peter Prof Dr M Strecker | Endoprosthesis implantable percutaneously in a patient's body |
KR940003548U (en) | 1992-08-14 | 1994-02-21 | 김형술 | Laundry dryer |
US5525357A (en) * | 1992-08-24 | 1996-06-11 | The United States Of America As Represented By The Department Of Health And Human Services | Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
US5650447A (en) | 1992-08-24 | 1997-07-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitric oxide-releasing polymers to treat restenosis and related disorders |
US5342621A (en) | 1992-09-15 | 1994-08-30 | Advanced Cardiovascular Systems, Inc. | Antithrombogenic surface |
US5770609A (en) | 1993-01-28 | 1998-06-23 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US6306421B1 (en) | 1992-09-25 | 2001-10-23 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5578075B1 (en) | 1992-11-04 | 2000-02-08 | Daynke Res Inc | Minimally invasive bioactivated endoprosthesis for vessel repair |
US5342348A (en) | 1992-12-04 | 1994-08-30 | Kaplan Aaron V | Method and device for treating and enlarging body lumens |
US5419760A (en) | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
CA2152594C (en) | 1993-01-19 | 1998-12-01 | David W. Mayer | Clad composite stent |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5595722A (en) * | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
US6663881B2 (en) | 1993-01-28 | 2003-12-16 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
US5441515A (en) | 1993-04-23 | 1995-08-15 | Advanced Cardiovascular Systems, Inc. | Ratcheting stent |
EP0621015B1 (en) | 1993-04-23 | 1998-03-18 | Schneider (Europe) Ag | Stent with a covering layer of elastic material and method for applying the layer on the stent |
US5464650A (en) | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
JPH08510451A (en) | 1993-05-13 | 1996-11-05 | ネオルックス コーポレイション | Prevention and treatment of pathogenesis associated with hyperproliferative smooth muscle cells |
US20030203976A1 (en) * | 1993-07-19 | 2003-10-30 | William L. Hunter | Anti-angiogenic compositions and methods of use |
EP2226085B1 (en) | 1993-07-19 | 2013-11-27 | Angiotech Pharmaceuticals, Inc. | Anti-angiogenic compositions and methods of use |
US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
JP4850985B2 (en) | 1993-07-29 | 2012-01-11 | アメリカ合衆国 | Method for treating atherosclerosis or restenosis using microtubule stabilizer |
US5380299A (en) * | 1993-08-30 | 1995-01-10 | Med Institute, Inc. | Thrombolytic treated intravascular medical device |
US6087479A (en) | 1993-09-17 | 2000-07-11 | Nitromed, Inc. | Localized use of nitric oxide-adducts to prevent internal tissue damage |
US5457113A (en) | 1993-10-15 | 1995-10-10 | Eli Lilly And Company | Methods for inhibiting vascular smooth muscle cell proliferation and restinosis |
US5415869A (en) | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
US5443497A (en) | 1993-11-22 | 1995-08-22 | The Johns Hopkins University | Percutaneous prosthetic by-pass graft and method of use |
US5554147A (en) * | 1994-02-01 | 1996-09-10 | Caphco, Inc. | Compositions and devices for controlled release of active ingredients |
US5556413A (en) | 1994-03-11 | 1996-09-17 | Advanced Cardiovascular Systems, Inc. | Coiled stent with locking ends |
US5733303A (en) | 1994-03-17 | 1998-03-31 | Medinol Ltd. | Flexible expandable stent |
US5843120A (en) | 1994-03-17 | 1998-12-01 | Medinol Ltd. | Flexible-expandable stent |
US5449373A (en) | 1994-03-17 | 1995-09-12 | Medinol Ltd. | Articulated stent |
US5636641A (en) | 1994-07-25 | 1997-06-10 | Advanced Cardiovascular Systems, Inc. | High strength member for intracorporeal use |
US5843741A (en) | 1994-08-01 | 1998-12-01 | Massachusetts Insitute Of Technology | Method for altering the differentiation of anchorage dependent cells on an electrically conducting polymer |
US5660873A (en) | 1994-09-09 | 1997-08-26 | Bioseal, Limited Liability Corporaton | Coating intraluminal stents |
US5891108A (en) * | 1994-09-12 | 1999-04-06 | Cordis Corporation | Drug delivery stent |
US5545210A (en) | 1994-09-22 | 1996-08-13 | Advanced Coronary Technology, Inc. | Method of implanting a permanent shape memory alloy stent |
US5817152A (en) | 1994-10-19 | 1998-10-06 | Birdsall; Matthew | Connected stent apparatus |
US5707385A (en) * | 1994-11-16 | 1998-01-13 | Advanced Cardiovascular Systems, Inc. | Drug loaded elastic membrane and method for delivery |
AU3783295A (en) | 1994-11-16 | 1996-05-23 | Advanced Cardiovascular Systems Inc. | Shape memory locking mechanism for intravascular stent |
CA2301351C (en) | 1994-11-28 | 2002-01-22 | Advanced Cardiovascular Systems, Inc. | Method and apparatus for direct laser cutting of metal stents |
US5665591A (en) | 1994-12-06 | 1997-09-09 | Trustees Of Boston University | Regulation of smooth muscle cell proliferation |
US5637113A (en) | 1994-12-13 | 1997-06-10 | Advanced Cardiovascular Systems, Inc. | Polymer film for wrapping a stent structure |
US6231600B1 (en) | 1995-02-22 | 2001-05-15 | Scimed Life Systems, Inc. | Stents with hybrid coating for medical devices |
AU719980B2 (en) | 1995-02-22 | 2000-05-18 | Menlo Care, Inc. | Covered expanding mesh stent |
GB9505721D0 (en) | 1995-03-21 | 1995-05-10 | Univ London | Expandable surgical stent |
US5605696A (en) * | 1995-03-30 | 1997-02-25 | Advanced Cardiovascular Systems, Inc. | Drug loaded polymeric material and method of manufacture |
US5837313A (en) | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
DE69623455T2 (en) | 1995-04-19 | 2003-01-16 | Schneider Usa Inc | COATED DILATATOR FOR DISPOSING A MEDICINAL PRODUCT |
US6120536A (en) | 1995-04-19 | 2000-09-19 | Schneider (Usa) Inc. | Medical devices with long term non-thrombogenic coatings |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US5575771A (en) | 1995-04-24 | 1996-11-19 | Walinsky; Paul | Balloon catheter with external guidewire |
US5766584A (en) | 1995-06-02 | 1998-06-16 | Massachusetts Institute Of Technology | Inhibition of vascular smooth muscle cell proliferation with implanted matrix containing vascular endothelial cells |
US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
US7550005B2 (en) * | 1995-06-07 | 2009-06-23 | Cook Incorporated | Coated implantable medical device |
CA2178541C (en) | 1995-06-07 | 2009-11-24 | Neal E. Fearnot | Implantable medical device |
US5609629A (en) | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
US7611533B2 (en) * | 1995-06-07 | 2009-11-03 | Cook Incorporated | Coated implantable medical device |
US5992769A (en) | 1995-06-09 | 1999-11-30 | The Regents Of The University Of Michigan | Microchannel system for fluid delivery |
PL184769B1 (en) | 1995-07-25 | 2002-12-31 | Medstent Inc | Expandible stent's mass |
DE19539449A1 (en) | 1995-10-24 | 1997-04-30 | Biotronik Mess & Therapieg | Process for the production of intraluminal stents from bioresorbable polymer material |
US5607442A (en) * | 1995-11-13 | 1997-03-04 | Isostent, Inc. | Stent with improved radiopacity and appearance characteristics |
US5741293A (en) | 1995-11-28 | 1998-04-21 | Wijay; Bandula | Locking stent |
US6017363A (en) * | 1997-09-22 | 2000-01-25 | Cordis Corporation | Bifurcated axially flexible stent |
US5843117A (en) | 1996-02-14 | 1998-12-01 | Inflow Dynamics Inc. | Implantable vascular and endoluminal stents and process of fabricating the same |
US6441025B2 (en) | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
US6334871B1 (en) * | 1996-03-13 | 2002-01-01 | Medtronic, Inc. | Radiopaque stent markers |
US5713949A (en) * | 1996-08-06 | 1998-02-03 | Jayaraman; Swaminathan | Microporous covered stents and method of coating |
US5725548A (en) * | 1996-04-08 | 1998-03-10 | Iowa India Investments Company Limited | Self-locking stent and method for its production |
US5928916A (en) | 1996-04-25 | 1999-07-27 | Medtronic, Inc. | Ionic attachment of biomolecules with a guanidino moiety to medical device surfaces |
US5922021A (en) | 1996-04-26 | 1999-07-13 | Jang; G. David | Intravascular stent |
US6783543B2 (en) * | 2000-06-05 | 2004-08-31 | Scimed Life Systems, Inc. | Intravascular stent with increasing coating retaining capacity |
US20040106985A1 (en) | 1996-04-26 | 2004-06-03 | Jang G. David | Intravascular stent |
US5617878A (en) | 1996-05-31 | 1997-04-08 | Taheri; Syde A. | Stent and method for treatment of aortic occlusive disease |
US5697971A (en) | 1996-06-11 | 1997-12-16 | Fischell; Robert E. | Multi-cell stent with cells having differing characteristics |
US7070590B1 (en) | 1996-07-02 | 2006-07-04 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
US5797898A (en) | 1996-07-02 | 1998-08-25 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
US6120535A (en) | 1996-07-29 | 2000-09-19 | Radiance Medical Systems, Inc. | Microporous tubular prosthesis |
US5922020A (en) | 1996-08-02 | 1999-07-13 | Localmed, Inc. | Tubular prosthesis having improved expansion and imaging characteristics |
US6007517A (en) | 1996-08-19 | 1999-12-28 | Anderson; R. David | Rapid exchange/perfusion angioplasty catheter |
US5797887A (en) | 1996-08-27 | 1998-08-25 | Novovasc Llc | Medical device with a surface adapted for exposure to a blood stream which is coated with a polymer containing a nitrosyl-containing organo-metallic compound which releases nitric oxide from the coating to mediate platelet aggregation |
US6057367A (en) | 1996-08-30 | 2000-05-02 | Duke University | Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses |
US5807404A (en) | 1996-09-19 | 1998-09-15 | Medinol Ltd. | Stent with variable features to optimize support and method of making such stent |
US6174326B1 (en) * | 1996-09-25 | 2001-01-16 | Terumo Kabushiki Kaisha | Radiopaque, antithrombogenic stent and method for its production |
US6099561A (en) | 1996-10-21 | 2000-08-08 | Inflow Dynamics, Inc. | Vascular and endoluminal stents with improved coatings |
US5824045A (en) | 1996-10-21 | 1998-10-20 | Inflow Dynamics Inc. | Vascular and endoluminal stents |
US5868781A (en) * | 1996-10-22 | 1999-02-09 | Scimed Life Systems, Inc. | Locking stent |
EP0934036B1 (en) | 1996-10-28 | 2004-03-03 | BIOTRONIK Mess- und Therapiegeräte GmbH & Co Ingenieurbüro Berlin | Stent |
ATE539702T1 (en) | 1996-11-04 | 2012-01-15 | Advanced Stent Tech Inc | DEVICE FOR EXPANDING A STENT AND METHOD FOR DEPLOYING IT |
ZA9710342B (en) | 1996-11-25 | 1998-06-10 | Alza Corp | Directional drug delivery stent and method of use. |
US5980972A (en) | 1996-12-20 | 1999-11-09 | Schneider (Usa) Inc | Method of applying drug-release coatings |
US5906759A (en) | 1996-12-26 | 1999-05-25 | Medinol Ltd. | Stent forming apparatus with stent deforming blades |
IT1289815B1 (en) | 1996-12-30 | 1998-10-16 | Sorin Biomedica Cardio Spa | ANGIOPLASTIC STENT AND RELATED PRODUCTION PROCESS |
US5733330A (en) | 1997-01-13 | 1998-03-31 | Advanced Cardiovascular Systems, Inc. | Balloon-expandable, crush-resistant locking stent |
JPH10204700A (en) | 1997-01-16 | 1998-08-04 | Nec Corp | Electrolytic polishing device for helix |
US5980551A (en) | 1997-02-07 | 1999-11-09 | Endovasc Ltd., Inc. | Composition and method for making a biodegradable drug delivery stent |
US5853419A (en) | 1997-03-17 | 1998-12-29 | Surface Genesis, Inc. | Stent |
US6240616B1 (en) | 1997-04-15 | 2001-06-05 | Advanced Cardiovascular Systems, Inc. | Method of manufacturing a medicated porous metal prosthesis |
US5843172A (en) * | 1997-04-15 | 1998-12-01 | Advanced Cardiovascular Systems, Inc. | Porous medicated stent |
US6273913B1 (en) | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
US6033433A (en) * | 1997-04-25 | 2000-03-07 | Scimed Life Systems, Inc. | Stent configurations including spirals |
US5843175A (en) | 1997-06-13 | 1998-12-01 | Global Therapeutics, Inc. | Enhanced flexibility surgical stent |
FR2764794B1 (en) | 1997-06-20 | 1999-11-12 | Nycomed Lab Sa | EXPANDED TUBULAR DEVICE WITH VARIABLE THICKNESS |
US5855600A (en) * | 1997-08-01 | 1999-01-05 | Inflow Dynamics Inc. | Flexible implantable stent with composite design |
US5899935A (en) | 1997-08-04 | 1999-05-04 | Schneider (Usa) Inc. | Balloon expandable braided stent with restraint |
US5984957A (en) | 1997-08-12 | 1999-11-16 | Schneider (Usa) Inc | Radially expanded prostheses with axial diameter control |
US6306166B1 (en) | 1997-08-13 | 2001-10-23 | Scimed Life Systems, Inc. | Loading and release of water-insoluble drugs |
US6159488A (en) | 1997-08-14 | 2000-12-12 | Agricultural Research Org. Ministry Of Agriculture (Gov.) | Intracoronary stents containing quinazolinone derivatives |
US6121027A (en) | 1997-08-15 | 2000-09-19 | Surmodics, Inc. | Polybifunctional reagent having a polymeric backbone and photoreactive moieties and bioactive groups |
US6569688B2 (en) | 1997-08-26 | 2003-05-27 | Technion Research & Development Foundation Ltd. | Intravascular apparatus method |
US6056722A (en) | 1997-09-18 | 2000-05-02 | Iowa-India Investments Company Limited Of Douglas | Delivery mechanism for balloons, drugs, stents and other physical/mechanical agents and methods of use |
JP4292710B2 (en) | 1997-09-24 | 2009-07-08 | エム イー ディ インスチィチュート インク | Radially expandable stent |
US6042606A (en) * | 1997-09-29 | 2000-03-28 | Cook Incorporated | Radially expandable non-axially contracting surgical stent |
US5972027A (en) * | 1997-09-30 | 1999-10-26 | Scimed Life Systems, Inc | Porous stent drug delivery system |
US5976182A (en) | 1997-10-03 | 1999-11-02 | Advanced Cardiovascular Systems, Inc. | Balloon-expandable, crush-resistant locking stent and method of loading the same |
KR100232852B1 (en) | 1997-10-15 | 1999-12-01 | 윤종용 | Inkjet printer head and method for fabricating thereof |
US5992000A (en) | 1997-10-16 | 1999-11-30 | Scimed Life Systems, Inc. | Stent crimper |
US6273908B1 (en) | 1997-10-24 | 2001-08-14 | Robert Ndondo-Lay | Stents |
US6309414B1 (en) | 1997-11-04 | 2001-10-30 | Sorin Biomedica Cardio S.P.A. | Angioplasty stents |
WO1999023977A1 (en) | 1997-11-07 | 1999-05-20 | Expandable Grafts Partnership | Intravascular stent and method for manufacturing an intravascular stent |
US6030414A (en) * | 1997-11-13 | 2000-02-29 | Taheri; Syde A. | Variable stent and method for treatment of arterial disease |
US6156062A (en) | 1997-12-03 | 2000-12-05 | Ave Connaught | Helically wrapped interlocking stent |
IT1296619B1 (en) | 1997-12-10 | 1999-07-14 | Sorin Biomedica Cardio Spa | PROCEDURE FOR THE TREATMENT OF OPEN STRUCTURE PROSTHESES AND RELATED DEVICES. |
US5964798A (en) | 1997-12-16 | 1999-10-12 | Cardiovasc, Inc. | Stent having high radial strength |
US6533807B2 (en) | 1998-02-05 | 2003-03-18 | Medtronic, Inc. | Radially-expandable stent and delivery system |
US6140127A (en) | 1998-02-18 | 2000-10-31 | Cordis Corporation | Method of coating an intravascular stent with an endothelial cell adhesive five amino acid peptide |
US6077296A (en) | 1998-03-04 | 2000-06-20 | Endologix, Inc. | Endoluminal vascular prosthesis |
US7208010B2 (en) | 2000-10-16 | 2007-04-24 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
US7179289B2 (en) | 1998-03-30 | 2007-02-20 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
EP1222941B2 (en) | 1998-03-30 | 2009-04-22 | Conor Medsystems, Inc. | Flexible medical device |
US6241762B1 (en) | 1998-03-30 | 2001-06-05 | Conor Medsystems, Inc. | Expandable medical device with ductile hinges |
US7208011B2 (en) * | 2001-08-20 | 2007-04-24 | Conor Medsystems, Inc. | Implantable medical device with drug filled holes |
US6019789A (en) * | 1998-04-01 | 2000-02-01 | Quanam Medical Corporation | Expandable unit cell and intraluminal stent |
US6206916B1 (en) * | 1998-04-15 | 2001-03-27 | Joseph G. Furst | Coated intraluminal graft |
US20010029351A1 (en) | 1998-04-16 | 2001-10-11 | Robert Falotico | Drug combinations and delivery devices for the prevention and treatment of vascular disease |
US6013099A (en) | 1998-04-29 | 2000-01-11 | Medtronic, Inc. | Medical device for delivering a water-insoluble therapeutic salt or substance |
US6206914B1 (en) * | 1998-04-30 | 2001-03-27 | Medtronic, Inc. | Implantable system with drug-eluting cells for on-demand local drug delivery |
US6423345B2 (en) * | 1998-04-30 | 2002-07-23 | Acusphere, Inc. | Matrices formed of polymer and hydrophobic compounds for use in drug delivery |
US6280411B1 (en) | 1998-05-18 | 2001-08-28 | Scimed Life Systems, Inc. | Localized delivery of drug agents |
US6083258A (en) | 1998-05-28 | 2000-07-04 | Yadav; Jay S. | Locking stent |
US6153252A (en) | 1998-06-30 | 2000-11-28 | Ethicon, Inc. | Process for coating stents |
AU5054499A (en) | 1998-07-21 | 2000-02-14 | Biocompatibles Limited | Coating |
US20020038146A1 (en) * | 1998-07-29 | 2002-03-28 | Ulf Harry | Expandable stent with relief cuts for carrying medicines and other materials |
AU771367B2 (en) | 1998-08-20 | 2004-03-18 | Cook Medical Technologies Llc | Coated implantable medical device |
JP2002523136A (en) | 1998-08-21 | 2002-07-30 | プロビデンス ヘルス システム−オレゴン | Insertable stent and method of making and using the stent |
US6203991B1 (en) | 1998-08-21 | 2001-03-20 | The Regents Of The University Of Michigan | Inhibition of smooth muscle cell migration by heme oxygenase I |
US7662409B2 (en) * | 1998-09-25 | 2010-02-16 | Gel-Del Technologies, Inc. | Protein matrix materials, devices and methods of making and using thereof |
US6206915B1 (en) * | 1998-09-29 | 2001-03-27 | Medtronic Ave, Inc. | Drug storing and metering stent |
US6293967B1 (en) | 1998-10-29 | 2001-09-25 | Conor Medsystems, Inc. | Expandable medical device with ductile hinges |
US6528121B2 (en) * | 1998-11-19 | 2003-03-04 | Dow Corning Toray Silicone Co., Ltd. | Aqueous treatment agent for wiping paper |
US6063101A (en) | 1998-11-20 | 2000-05-16 | Precision Vascular Systems, Inc. | Stent apparatus and method |
PT1013647E (en) | 1998-12-21 | 2003-04-30 | Lonza Ag | PREPARATION PROCESS OF N- (AMINO-4,6-DIHALOGENOPYRIMIDINE) -FORMAMIDES |
US6120847A (en) | 1999-01-08 | 2000-09-19 | Scimed Life Systems, Inc. | Surface treatment method for stent coating |
US6530950B1 (en) * | 1999-01-12 | 2003-03-11 | Quanam Medical Corporation | Intraluminal stent having coaxial polymer member |
US6273910B1 (en) | 1999-03-11 | 2001-08-14 | Advanced Cardiovascular Systems, Inc. | Stent with varying strut geometry |
US6730116B1 (en) | 1999-04-16 | 2004-05-04 | Medtronic, Inc. | Medical device for intraluminal endovascular stenting |
US6287335B1 (en) | 1999-04-26 | 2001-09-11 | William J. Drasler | Intravascular folded tubular endoprosthesis |
US6334807B1 (en) * | 1999-04-30 | 2002-01-01 | International Business Machines Corporation | Chemical mechanical polishing in-situ end point system |
US6245101B1 (en) | 1999-05-03 | 2001-06-12 | William J. Drasler | Intravascular hinge stent |
US6375676B1 (en) | 1999-05-17 | 2002-04-23 | Advanced Cardiovascular Systems, Inc. | Self-expanding stent with enhanced delivery precision and stent delivery system |
US6290673B1 (en) * | 1999-05-20 | 2001-09-18 | Conor Medsystems, Inc. | Expandable medical device delivery system and method |
US6872225B1 (en) * | 1999-05-27 | 2005-03-29 | Biocompatibles Uk Limited | Local drug delivery |
CA2379909C (en) | 1999-08-06 | 2011-01-04 | Board Of Regents, The University Of Texas System | Drug releasing biodegradable fiber implant |
US7807211B2 (en) | 1999-09-03 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Thermal treatment of an implantable medical device |
US6379381B1 (en) | 1999-09-03 | 2002-04-30 | Advanced Cardiovascular Systems, Inc. | Porous prosthesis and a method of depositing substances into the pores |
US6790228B2 (en) | 1999-12-23 | 2004-09-14 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US6713119B2 (en) | 1999-09-03 | 2004-03-30 | Advanced Cardiovascular Systems, Inc. | Biocompatible coating for a prosthesis and a method of forming the same |
US6503954B1 (en) * | 2000-03-31 | 2003-01-07 | Advanced Cardiovascular Systems, Inc. | Biocompatible carrier containing actinomycin D and a method of forming the same |
DE60032912T2 (en) * | 1999-09-03 | 2007-10-25 | Advanced Cardiovascular Systems, Inc., Santa Clara | POROUS PROSTHESIS AND METHOD FOR THE DEPOSITION OF SUBSTANCES IN THE PORES |
US7682647B2 (en) | 1999-09-03 | 2010-03-23 | Advanced Cardiovascular Systems, Inc. | Thermal treatment of a drug eluting implantable medical device |
US6759054B2 (en) | 1999-09-03 | 2004-07-06 | Advanced Cardiovascular Systems, Inc. | Ethylene vinyl alcohol composition and coating |
US6239118B1 (en) | 1999-10-05 | 2001-05-29 | Richard A. Schatz | Method for preventing restenosis using a substituted adenine derivative |
US6682545B1 (en) * | 1999-10-06 | 2004-01-27 | The Penn State Research Foundation | System and device for preventing restenosis in body vessels |
WO2001026584A1 (en) | 1999-10-14 | 2001-04-19 | United Stenting, Inc. | Stents with multilayered struts |
US6331189B1 (en) | 1999-10-18 | 2001-12-18 | Medtronic, Inc. | Flexible medical stent |
US6428569B1 (en) * | 1999-11-09 | 2002-08-06 | Scimed Life Systems Inc. | Micro structure stent configurations |
US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
EP1229901B1 (en) * | 1999-11-17 | 2009-03-18 | Boston Scientific Limited | Microfabricated devices for the delivery of molecules into a carrier fluid |
US6613432B2 (en) | 1999-12-22 | 2003-09-02 | Biosurface Engineering Technologies, Inc. | Plasma-deposited coatings, devices and methods |
US6338739B1 (en) | 1999-12-22 | 2002-01-15 | Ethicon, Inc. | Biodegradable stent |
US6908624B2 (en) | 1999-12-23 | 2005-06-21 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US6471979B2 (en) * | 1999-12-29 | 2002-10-29 | Estrogen Vascular Technology, Llc | Apparatus and method for delivering compounds to a living organism |
US6491617B1 (en) | 1999-12-30 | 2002-12-10 | St. Jude Medical, Inc. | Medical devices that resist restenosis |
AU2623201A (en) | 1999-12-30 | 2001-07-16 | Kam W Leong | Controlled delivery of therapeutic agents by insertable medical devices |
ATE310542T1 (en) | 2000-01-24 | 2005-12-15 | Biocompatibles Uk Ltd | COATED IMPLANTS |
US6375826B1 (en) | 2000-02-14 | 2002-04-23 | Advanced Cardiovascular Systems, Inc. | Electro-polishing fixture and electrolyte solution for polishing stents and method |
US7828835B2 (en) * | 2000-03-01 | 2010-11-09 | Medinol Ltd. | Longitudinally flexible stent |
ATE499988T1 (en) | 2000-03-02 | 2011-03-15 | Microchips Inc | MICROMECHANICAL DEVICES AND METHODS FOR STORAGE AND SELECTIVE EXPOSURE OF CHEMICALS |
EP1132058A1 (en) | 2000-03-06 | 2001-09-12 | Advanced Laser Applications Holding S.A. | Intravascular prothesis |
US6379382B1 (en) | 2000-03-13 | 2002-04-30 | Jun Yang | Stent having cover with drug delivery capability |
US20040243097A1 (en) | 2000-05-12 | 2004-12-02 | Robert Falotico | Antiproliferative drug and delivery device |
US20020007214A1 (en) * | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US20020005206A1 (en) * | 2000-05-19 | 2002-01-17 | Robert Falotico | Antiproliferative drug and delivery device |
US20050002986A1 (en) | 2000-05-12 | 2005-01-06 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US6776796B2 (en) * | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
US20020007215A1 (en) * | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US7300662B2 (en) | 2000-05-12 | 2007-11-27 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US7419678B2 (en) | 2000-05-12 | 2008-09-02 | Cordis Corporation | Coated medical devices for the prevention and treatment of vascular disease |
US20020007213A1 (en) * | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
WO2001087368A1 (en) | 2000-05-16 | 2001-11-22 | Ortho-Mcneil Pharmaceutical, Inc. | Process for coating medical devices using super-critical carbon dioxide |
US6673385B1 (en) * | 2000-05-31 | 2004-01-06 | Advanced Cardiovascular Systems, Inc. | Methods for polymeric coatings stents |
US6395326B1 (en) | 2000-05-31 | 2002-05-28 | Advanced Cardiovascular Systems, Inc. | Apparatus and method for depositing a coating onto a surface of a prosthesis |
US6723373B1 (en) | 2000-06-16 | 2004-04-20 | Cordis Corporation | Device and process for coating stents |
US6585765B1 (en) | 2000-06-29 | 2003-07-01 | Advanced Cardiovascular Systems, Inc. | Implantable device having substances impregnated therein and a method of impregnating the same |
US20020077693A1 (en) | 2000-12-19 | 2002-06-20 | Barclay Bruce J. | Covered, coiled drug delivery stent and method |
US6709451B1 (en) | 2000-07-14 | 2004-03-23 | Norman Noble, Inc. | Channeled vascular stent apparatus and method |
US6555157B1 (en) | 2000-07-25 | 2003-04-29 | Advanced Cardiovascular Systems, Inc. | Method for coating an implantable device and system for performing the method |
US6548308B2 (en) | 2000-09-25 | 2003-04-15 | Picoliter Inc. | Focused acoustic energy method and device for generating droplets of immiscible fluids |
US6805898B1 (en) | 2000-09-28 | 2004-10-19 | Advanced Cardiovascular Systems, Inc. | Surface features of an implantable medical device |
US6716444B1 (en) | 2000-09-28 | 2004-04-06 | Advanced Cardiovascular Systems, Inc. | Barriers for polymer-coated implantable medical devices and methods for making the same |
US6254632B1 (en) | 2000-09-28 | 2001-07-03 | Advanced Cardiovascular Systems, Inc. | Implantable medical device having protruding surface structures for drug delivery and cover attachment |
US6953560B1 (en) | 2000-09-28 | 2005-10-11 | Advanced Cardiovascular Systems, Inc. | Barriers for polymer-coated implantable medical devices and methods for making the same |
US6746773B2 (en) | 2000-09-29 | 2004-06-08 | Ethicon, Inc. | Coatings for medical devices |
DE20122506U1 (en) * | 2000-10-16 | 2005-12-08 | Conor Medsystems, Inc., Menlo Park | Expandable medical device for delivering a beneficial agent |
US6764507B2 (en) | 2000-10-16 | 2004-07-20 | Conor Medsystems, Inc. | Expandable medical device with improved spatial distribution |
US6506437B1 (en) * | 2000-10-17 | 2003-01-14 | Advanced Cardiovascular Systems, Inc. | Methods of coating an implantable device having depots formed in a surface thereof |
US6558733B1 (en) | 2000-10-26 | 2003-05-06 | Advanced Cardiovascular Systems, Inc. | Method for etching a micropatterned microdepot prosthesis |
US6783793B1 (en) | 2000-10-26 | 2004-08-31 | Advanced Cardiovascular Systems, Inc. | Selective coating of medical devices |
US6758859B1 (en) | 2000-10-30 | 2004-07-06 | Kenny L. Dang | Increased drug-loading and reduced stress drug delivery device |
US10398830B2 (en) * | 2000-11-17 | 2019-09-03 | Vactronix Scientific, Llc | Device for in vivo delivery of bioactive agents and method of manufacture thereof |
EP1347794A2 (en) | 2000-11-27 | 2003-10-01 | Medtronic, Inc. | Stents and methods for preparing stents from wires having hydrogel coating layers thereon |
WO2002043788A2 (en) * | 2000-11-28 | 2002-06-06 | Boston Scientific Limited | Method and apparatus for delivery of therapeutic from a delivery matrix |
US6517888B1 (en) | 2000-11-28 | 2003-02-11 | Scimed Life Systems, Inc. | Method for manufacturing a medical device having a coated portion by laser ablation |
WO2002059261A2 (en) | 2000-12-07 | 2002-08-01 | The Medstar Research Institute | Inhibition of restenosis using a dna-coated stent |
US6545097B2 (en) * | 2000-12-12 | 2003-04-08 | Scimed Life Systems, Inc. | Drug delivery compositions and medical devices containing block copolymer |
US7077859B2 (en) | 2000-12-22 | 2006-07-18 | Avantec Vascular Corporation | Apparatus and methods for variably controlled substance delivery from implanted prostheses |
US6929660B1 (en) | 2000-12-22 | 2005-08-16 | Advanced Cardiovascular Systems, Inc. | Intravascular stent |
US20030033007A1 (en) * | 2000-12-22 | 2003-02-13 | Avantec Vascular Corporation | Methods and devices for delivery of therapeutic capable agents with variable release profile |
US20020082679A1 (en) | 2000-12-22 | 2002-06-27 | Avantec Vascular Corporation | Delivery or therapeutic capable agents |
US6663662B2 (en) | 2000-12-28 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Diffusion barrier layer for implantable devices |
US6635082B1 (en) | 2000-12-29 | 2003-10-21 | Advanced Cardiovascular Systems Inc. | Radiopaque stent |
GB0100761D0 (en) * | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
GB0100760D0 (en) * | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
GB2371066B8 (en) | 2001-01-16 | 2012-12-19 | Halliburton Energy Serv Inc | Tubulars with expandable cells and locking mechanisms |
US6706274B2 (en) | 2001-01-18 | 2004-03-16 | Scimed Life Systems, Inc. | Differential delivery of nitric oxide |
US6752829B2 (en) * | 2001-01-30 | 2004-06-22 | Scimed Life Systems, Inc. | Stent with channel(s) for containing and delivering a biologically active material and method for manufacturing the same |
US20040204756A1 (en) | 2004-02-11 | 2004-10-14 | Diaz Stephen Hunter | Absorbent article with improved liquid acquisition capacity |
US6964680B2 (en) | 2001-02-05 | 2005-11-15 | Conor Medsystems, Inc. | Expandable medical device with tapered hinge |
US20040073294A1 (en) * | 2002-09-20 | 2004-04-15 | Conor Medsystems, Inc. | Method and apparatus for loading a beneficial agent into an expandable medical device |
US20040220660A1 (en) | 2001-02-05 | 2004-11-04 | Shanley John F. | Bioresorbable stent with beneficial agent reservoirs |
US20020127263A1 (en) | 2001-02-27 | 2002-09-12 | Wenda Carlyle | Peroxisome proliferator-acitvated receptor gamma ligand eluting medical device |
US20050278014A9 (en) | 2001-03-07 | 2005-12-15 | Wolfgang Daum | Stent and method for drug delivery from stents |
WO2002072014A2 (en) * | 2001-03-08 | 2002-09-19 | Volcano Therapeutics, Inc. | Medical devices, compositions and methods for treating vulnerable plaque |
US6378988B1 (en) | 2001-03-19 | 2002-04-30 | Microfab Technologies, Inc. | Cartridge element for micro jet dispensing |
US20020138136A1 (en) | 2001-03-23 | 2002-09-26 | Scimed Life Systems, Inc. | Medical device having radio-opacification and barrier layers |
US6780424B2 (en) | 2001-03-30 | 2004-08-24 | Charles David Claude | Controlled morphologies in polymer drug for release of drugs from polymer films |
US6712845B2 (en) | 2001-04-24 | 2004-03-30 | Advanced Cardiovascular Systems, Inc. | Coating for a stent and a method of forming the same |
US6660034B1 (en) | 2001-04-30 | 2003-12-09 | Advanced Cardiovascular Systems, Inc. | Stent for increasing blood flow to ischemic tissues and a method of using the same |
US6599415B1 (en) | 2001-04-30 | 2003-07-29 | Advanced Cardiovascular Systems, Inc. | Apparatus and method for electropolishing surfaces |
US6605154B1 (en) | 2001-05-31 | 2003-08-12 | Advanced Cardiovascular Systems, Inc. | Stent mounting device |
US6679980B1 (en) * | 2001-06-13 | 2004-01-20 | Advanced Cardiovascular Systems, Inc. | Apparatus for electropolishing a stent |
US7493162B2 (en) | 2001-06-15 | 2009-02-17 | Cardiac Pacemakers, Inc. | Pulmonary vein stent for treating atrial fibrillation |
US7247313B2 (en) | 2001-06-27 | 2007-07-24 | Advanced Cardiovascular Systems, Inc. | Polyacrylates coatings for implantable medical devices |
US6695920B1 (en) | 2001-06-27 | 2004-02-24 | Advanced Cardiovascular Systems, Inc. | Mandrel for supporting a stent and a method of using the mandrel to coat a stent |
US6656216B1 (en) | 2001-06-29 | 2003-12-02 | Advanced Cardiovascular Systems, Inc. | Composite stent with regioselective material |
US6676987B2 (en) * | 2001-07-02 | 2004-01-13 | Scimed Life Systems, Inc. | Coating a medical appliance with a bubble jet printing head |
US6682771B2 (en) * | 2001-07-02 | 2004-01-27 | Scimed Life Systems, Inc. | Coating dispensing system and method using a solenoid head for coating medical devices |
US20030050687A1 (en) * | 2001-07-03 | 2003-03-13 | Schwade Nathan D. | Biocompatible stents and method of deployment |
DE60120955T3 (en) | 2001-07-20 | 2015-06-25 | Cid S.P.A. | stent |
JP2003036944A (en) * | 2001-07-25 | 2003-02-07 | Sumitomo Wiring Syst Ltd | Connector |
US7056338B2 (en) | 2003-03-28 | 2006-06-06 | Conor Medsystems, Inc. | Therapeutic agent delivery device with controlled therapeutic agent release rates |
US20040249443A1 (en) | 2001-08-20 | 2004-12-09 | Shanley John F. | Expandable medical device for treating cardiac arrhythmias |
DE60238422D1 (en) | 2001-09-24 | 2011-01-05 | Boston Scient Ltd | OPTIMIZED DOSAGE IN PACLITAXELIC STENTS |
US20050025808A1 (en) | 2001-09-24 | 2005-02-03 | Herrmann Robert A. | Medical devices and methods for inhibiting smooth muscle cell proliferation |
US7195640B2 (en) * | 2001-09-25 | 2007-03-27 | Cordis Corporation | Coated medical devices for the treatment of vulnerable plaque |
US6753071B1 (en) | 2001-09-27 | 2004-06-22 | Advanced Cardiovascular Systems, Inc. | Rate-reducing membrane for release of an agent |
DE10150995A1 (en) * | 2001-10-08 | 2003-04-10 | Biotronik Mess & Therapieg | Implant e.g. a stent, comprises a decomposable substance which allows contact between the cell proliferation inhibitor and the stent surroundings only after a specified time |
US20030077312A1 (en) | 2001-10-22 | 2003-04-24 | Ascher Schmulewicz | Coated intraluminal stents and reduction of restenosis using same |
US6939376B2 (en) * | 2001-11-05 | 2005-09-06 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
US20030088307A1 (en) | 2001-11-05 | 2003-05-08 | Shulze John E. | Potent coatings for stents |
EP1310242A1 (en) | 2001-11-13 | 2003-05-14 | SORIN BIOMEDICA CARDIO S.p.A. | Carrier and kit for endoluminal delivery of active principles |
US7014654B2 (en) | 2001-11-30 | 2006-03-21 | Scimed Life Systems, Inc. | Stent designed for the delivery of therapeutic substance or other agents |
US6939374B2 (en) | 2001-12-21 | 2005-09-06 | Scimed Life Systems, Inc. | Stents, stenting systems, and related methods for agent delivery |
DE20200220U1 (en) * | 2002-01-08 | 2002-03-21 | Translumina Gmbh | stent |
US6911040B2 (en) | 2002-01-24 | 2005-06-28 | Cordis Corporation | Covered segmented stent |
US7445629B2 (en) | 2002-01-31 | 2008-11-04 | Boston Scientific Scimed, Inc. | Medical device for delivering biologically active material |
US20030181973A1 (en) | 2002-03-20 | 2003-09-25 | Harvinder Sahota | Reduced restenosis drug containing stents |
US6743463B2 (en) | 2002-03-28 | 2004-06-01 | Scimed Life Systems, Inc. | Method for spray-coating a medical device having a tubular wall such as a stent |
US20030204239A1 (en) | 2002-04-26 | 2003-10-30 | Wenda Carlyle | Endovascular stent with a preservative coating |
US6645547B1 (en) | 2002-05-02 | 2003-11-11 | Labcoat Ltd. | Stent coating device |
US6670612B1 (en) * | 2002-07-01 | 2003-12-30 | Kla-Tencor Technologies Corporation | Undercut measurement using SEM |
AU2003276920A1 (en) | 2002-09-20 | 2004-04-08 | Innovational Holdings, Llc | Expandable medical device with openings for delivery of multiple beneficial agents |
US20040127976A1 (en) | 2002-09-20 | 2004-07-01 | Conor Medsystems, Inc. | Method and apparatus for loading a beneficial agent into an expandable medical device |
US6818063B1 (en) | 2002-09-24 | 2004-11-16 | Advanced Cardiovascular Systems, Inc. | Stent mandrel fixture and method for minimizing coating defects |
US6702850B1 (en) | 2002-09-30 | 2004-03-09 | Mediplex Corporation Korea | Multi-coated drug-eluting stent for antithrombosis and antirestenosis |
US20040142014A1 (en) | 2002-11-08 | 2004-07-22 | Conor Medsystems, Inc. | Method and apparatus for reducing tissue damage after ischemic injury |
EP1560613A1 (en) | 2002-11-08 | 2005-08-10 | Conor Medsystems, Inc. | Method and apparatus for reducing tissue damage after ischemic injury |
CA2505576A1 (en) | 2002-11-08 | 2004-05-27 | Conor Medsystems, Inc. | Expandable medical device and method for treating chronic total occlusions with local delivery of an angiogenic factor |
US6896965B1 (en) | 2002-11-12 | 2005-05-24 | Advanced Cardiovascular Systems, Inc. | Rate limiting barriers for implantable devices |
WO2004045578A2 (en) | 2002-11-15 | 2004-06-03 | Novartis Ag | Drug delivery system |
US6982004B1 (en) | 2002-11-26 | 2006-01-03 | Advanced Cardiovascular Systems, Inc. | Electrostatic loading of drugs on implantable medical devices |
US20050079199A1 (en) | 2003-02-18 | 2005-04-14 | Medtronic, Inc. | Porous coatings for drug release from medical devices |
US6926919B1 (en) | 2003-02-26 | 2005-08-09 | Advanced Cardiovascular Systems, Inc. | Method for fabricating a coating for a medical device |
US8088404B2 (en) | 2003-03-20 | 2012-01-03 | Medtronic Vasular, Inc. | Biocompatible controlled release coatings for medical devices and related methods |
WO2005016396A1 (en) | 2003-08-13 | 2005-02-24 | Poly-Med, Inc. | Biocompatible controlled release coatings for medical devices and related methods |
US20040202692A1 (en) | 2003-03-28 | 2004-10-14 | Conor Medsystems, Inc. | Implantable medical device and method for in situ selective modulation of agent delivery |
US7482034B2 (en) | 2003-04-24 | 2009-01-27 | Boston Scientific Scimed, Inc. | Expandable mask stent coating method |
EP1470828A1 (en) | 2003-04-25 | 2004-10-27 | Medtronic Vascular, Inc. | Plasticized stent coatings |
US20040247671A1 (en) | 2003-04-25 | 2004-12-09 | Prescott James H. | Solid drug formulation and device for storage and controlled delivery thereof |
US20040215311A1 (en) | 2003-04-28 | 2004-10-28 | Kantor John D. | Method and system for improving stent retention using stent openings |
US6923996B2 (en) | 2003-05-06 | 2005-08-02 | Scimed Life Systems, Inc. | Processes for producing polymer coatings for release of therapeutic agent |
US7279174B2 (en) | 2003-05-08 | 2007-10-09 | Advanced Cardiovascular Systems, Inc. | Stent coatings comprising hydrophilic additives |
US7524527B2 (en) | 2003-05-19 | 2009-04-28 | Boston Scientific Scimed, Inc. | Electrostatic coating of a device |
EP2433661A1 (en) | 2003-05-28 | 2012-03-28 | Conor Medsystems, Inc. | Anti-restenotic agents to be delivered from a stent |
US7169179B2 (en) | 2003-06-05 | 2007-01-30 | Conor Medsystems, Inc. | Drug delivery device and method for bi-directional drug delivery |
US7186789B2 (en) | 2003-06-11 | 2007-03-06 | Advanced Cardiovascular Systems, Inc. | Bioabsorbable, biobeneficial polyester polymers for use in drug eluting stent coatings |
US20050118344A1 (en) | 2003-12-01 | 2005-06-02 | Pacetti Stephen D. | Temperature controlled crimping |
JP2005046611A (en) | 2003-07-01 | 2005-02-24 | Medtronic Vascular Inc | Adhesive layer activated by energy for stent coated with polymer containing medicament |
US20060210600A1 (en) | 2003-07-07 | 2006-09-21 | Medtronic Vascular, Inc. | Coated stent with timed release of multiple therapeutic agents to inhibit restenosis adjacent to the stent ends |
US7318945B2 (en) | 2003-07-09 | 2008-01-15 | Medtronic Vascular, Inc. | Laminated drug-polymer coated stent having dipped layers |
US20050033417A1 (en) | 2003-07-31 | 2005-02-10 | John Borges | Coating for controlled release of a therapeutic agent |
US7357940B2 (en) | 2003-07-31 | 2008-04-15 | Boston Scientific Scimed, Inc. | Implantable or insertable medical devices containing graft copolymer for controlled delivery of therapeutic agents |
US8870814B2 (en) | 2003-07-31 | 2014-10-28 | Boston Scientific Scimed, Inc. | Implantable or insertable medical devices containing silicone copolymer for controlled delivery of therapeutic agent |
US20050037047A1 (en) | 2003-08-11 | 2005-02-17 | Young-Ho Song | Medical devices comprising spray dried microparticles |
US20050049693A1 (en) | 2003-08-25 | 2005-03-03 | Medtronic Vascular Inc. | Medical devices and compositions for delivering biophosphonates to anatomical sites at risk for vascular disease |
US20050055078A1 (en) | 2003-09-04 | 2005-03-10 | Medtronic Vascular, Inc. | Stent with outer slough coating |
US20050060020A1 (en) | 2003-09-17 | 2005-03-17 | Scimed Life Systems, Inc. | Covered stent with biologically active material |
US7785653B2 (en) | 2003-09-22 | 2010-08-31 | Innovational Holdings Llc | Method and apparatus for loading a beneficial agent into an expandable medical device |
US8801692B2 (en) | 2003-09-24 | 2014-08-12 | Medtronic Vascular, Inc. | Gradient coated stent and method of fabrication |
US7060319B2 (en) | 2003-09-24 | 2006-06-13 | Boston Scientific Scimed, Inc. | method for using an ultrasonic nozzle to coat a medical appliance |
US7055237B2 (en) | 2003-09-29 | 2006-06-06 | Medtronic Vascular, Inc. | Method of forming a drug eluting stent |
US7744645B2 (en) | 2003-09-29 | 2010-06-29 | Medtronic Vascular, Inc. | Laminated drug-polymer coated stent with dipped and cured layers |
US7198675B2 (en) | 2003-09-30 | 2007-04-03 | Advanced Cardiovascular Systems | Stent mandrel fixture and method for selectively coating surfaces of a stent |
CA2541138A1 (en) | 2003-10-06 | 2005-05-06 | Novartis Ag | Use of genetic polymorphisms that associate with efficacy of treatment of inflammatory disease |
US7704544B2 (en) | 2003-10-07 | 2010-04-27 | Advanced Cardiovascular Systems, Inc. | System and method for coating a tubular implantable medical device |
US6984411B2 (en) | 2003-10-14 | 2006-01-10 | Boston Scientific Scimed, Inc. | Method for roll coating multiple stents |
US20050087520A1 (en) | 2003-10-28 | 2005-04-28 | Lixiao Wang | Method and apparatus for selective ablation of coatings from medical devices |
US20050100577A1 (en) | 2003-11-10 | 2005-05-12 | Parker Theodore L. | Expandable medical device with beneficial agent matrix formed by a multi solvent system |
US20050112170A1 (en) | 2003-11-20 | 2005-05-26 | Hossainy Syed F. | Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same |
WO2005053937A1 (en) | 2003-12-01 | 2005-06-16 | Advanced Cardiovascular Systems, Inc. | Temperature controlled crimping |
US7303758B2 (en) | 2004-01-20 | 2007-12-04 | Cordis Corporation | Local vascular delivery of mycophenolic acid in combination with rapamycin to prevent restenosis following vascular injury |
ITTO20040056A1 (en) | 2004-02-05 | 2004-05-05 | Sorin Biomedica Cardio Spa | STENT FOR THE ENDOLIMINAL DELIVERY OF PRINCIPLES OR ACTIVE AGENTS |
US7806924B2 (en) | 2004-02-18 | 2010-10-05 | Cordis Corporation | Implantable structures for local vascular delivery of cladribine in combination with rapamycin for restenosis |
US20050197691A1 (en) | 2004-02-18 | 2005-09-08 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
US8137397B2 (en) | 2004-02-26 | 2012-03-20 | Boston Scientific Scimed, Inc. | Medical devices |
US7294145B2 (en) | 2004-02-26 | 2007-11-13 | Boston Scientific Scimed, Inc. | Stent with differently coated inside and outside surfaces |
US8828416B2 (en) | 2004-03-09 | 2014-09-09 | Cordis Corporation | Local vascular delivery of topotecan in combination with rapamycin to prevent restenosis following vascular injury |
US6979473B2 (en) | 2004-03-15 | 2005-12-27 | Boston Scientific Scimed, Inc. | Method for fine bore orifice spray coating of medical devices and pre-filming atomization |
US20050208093A1 (en) | 2004-03-22 | 2005-09-22 | Thierry Glauser | Phosphoryl choline coating compositions |
US7875282B2 (en) | 2004-03-22 | 2011-01-25 | Cordis Corporation | Coated medical device for local vascular delivery of Panzem® in combination with rapamycin to prevent restenosis following vascular injury |
WO2005094930A1 (en) | 2004-03-23 | 2005-10-13 | Boston Scientific Limited | Agent eluting stent and catheter |
US20050214339A1 (en) | 2004-03-29 | 2005-09-29 | Yiwen Tang | Biologically degradable compositions for medical applications |
US20050220836A1 (en) | 2004-03-31 | 2005-10-06 | Robert Falotico | Drug delivery device |
US8007737B2 (en) | 2004-04-14 | 2011-08-30 | Wyeth | Use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices |
CA2502018A1 (en) | 2004-04-16 | 2005-10-16 | Conor Medsystems, Inc. | Bioresorbable stent delivery system |
US8048149B2 (en) | 2004-05-13 | 2011-11-01 | Medtronic Vascular, Inc. | Intraluminal stent including therapeutic agent delivery pads, and method of manufacturing the same |
US20050261757A1 (en) | 2004-05-21 | 2005-11-24 | Conor Medsystems, Inc. | Stent with contoured bridging element |
US20050261762A1 (en) | 2004-05-21 | 2005-11-24 | Medtronic Vascular, Inc. | Medical devices to prevent or inhibit restenosis |
US20060020329A1 (en) | 2004-05-26 | 2006-01-26 | Medtronic Vascular, Inc. | Semi-directional drug delivering stents |
WO2005120549A2 (en) | 2004-06-07 | 2005-12-22 | Conor Medsystems, Inc. | Local delivery of growth factors for stem cell transplantation |
US7365007B2 (en) * | 2004-06-30 | 2008-04-29 | Intel Corporation | Interconnects with direct metalization and conductive polymer |
AU2005314565B2 (en) | 2004-12-08 | 2012-02-02 | Innovational Holdings, Llc | Expandable medical device with differential hinge performance |
-
2004
- 2004-03-29 EP EP04758550A patent/EP1610823B1/en not_active Expired - Lifetime
- 2004-03-29 WO PCT/US2004/009602 patent/WO2004087214A1/en active Application Filing
- 2004-03-29 JP JP2006509440A patent/JP5596896B2/en not_active Expired - Fee Related
- 2004-03-29 AT AT04758550T patent/ATE526038T1/en not_active IP Right Cessation
- 2004-03-29 EP EP10010594.9A patent/EP2289571B1/en not_active Expired - Lifetime
- 2004-03-29 CA CA2519711A patent/CA2519711C/en not_active Expired - Fee Related
- 2004-03-29 AU AU2004226327A patent/AU2004226327A1/en not_active Abandoned
- 2004-03-29 EP EP10010593A patent/EP2272544A1/en not_active Withdrawn
-
2006
- 2006-03-07 US US11/369,592 patent/US8449901B2/en not_active Expired - Fee Related
-
2013
- 2013-03-26 US US13/850,605 patent/US20130209663A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20060147489A1 (en) | 2006-07-06 |
JP2006523501A (en) | 2006-10-19 |
CA2519711A1 (en) | 2004-10-14 |
EP2289571A1 (en) | 2011-03-02 |
EP1610823A1 (en) | 2006-01-04 |
EP2289571B1 (en) | 2016-08-03 |
WO2004087214A1 (en) | 2004-10-14 |
JP5596896B2 (en) | 2014-09-24 |
ATE526038T1 (en) | 2011-10-15 |
EP2272544A1 (en) | 2011-01-12 |
US8449901B2 (en) | 2013-05-28 |
US20130209663A1 (en) | 2013-08-15 |
AU2004226327A1 (en) | 2004-10-14 |
EP1610823B1 (en) | 2011-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2519711C (en) | Implantable medical device with beneficial agent concentration gradient | |
CA2611117C (en) | Implantable medical device with openings for delivery of beneficial agents with combination release kinetics | |
CA2561156C (en) | Bioresorbable stent with beneficial agent reservoirs | |
US20050100577A1 (en) | Expandable medical device with beneficial agent matrix formed by a multi solvent system | |
US8986775B2 (en) | System and method for loading a beneficial agent into a medical device | |
US20050010170A1 (en) | Implantable medical device with beneficial agent concentration gradient | |
US20050234538A1 (en) | Bioresorbable stent delivery system | |
JP2006523501A5 (en) | ||
EP2433661A1 (en) | Anti-restenotic agents to be delivered from a stent | |
WO2008024626A2 (en) | Bioresorbable stent with extended in vivo release of anti-restenotic agent | |
US20060204546A1 (en) | Methods and systems for delivering immunosuppressant and anti-inflammatory agents from a stent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20190329 |